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ABSTRACT 
The interplay between genetic and environmental factors is central to childhood asthma and 
allergic disease. Transmitted and acquired risk factors collaborate to produce the phenotypic 
variation of a trait within the population. In this work, we have employed studies of twins to 
illustrate the relationship between twinship itself, early growth, and genetic and epigenetic 
factors with childhood asthma.  
Twins have been suggested to be a high risk group for asthma. Study I was a large 
population-based register study of twinship in itself as a risk factor for childhood asthma. 
Asthma diagnoses and medication use among Swedish twins and singletons born 1993-2001 
and 2005-2009 were compared before and after controlling for birth weight and gestational 
age. In the younger group, twins were at higher risk of developing asthma before controlling 
for perinatal factors – afterwards, twins were at lower risk of asthma in both age groups. This 
suggests that important mechanisms for asthma are shared between twins and singletons. 
Low birth weight and rapid early growth have been shown to increase the risk of asthma. The 
aim of Study II was to describe the association between early growth and asthma in twins. 
Height and weight from 0 to 3 years of age were modelled in 2,874 twins. There was an 
association between later timing of maximum growth velocity and asthma both in terms of 
weight and height, although this relationship did not remain after controlling for birth weight 
or gestational age, which indicates that early postnatal growth may primarily be of interest as 
an extension of preceding foetal growth. 
There is significant comorbidity between asthma and other allergic diseases. In Study III, we 
studied the influence of genetic factors on childhood asthma, hay fever, atopic eczema and 
food allergy. Using twin models and data from 25,306 twins, we concluded that asthma and 
all of the other allergic phenotypes were highly influenced by additive genetic effects. A pre-
selected set of high-risk genetic variants were primarily associated with asthma or both 
asthma and hay fever (rs3771180 in IL1RL1). 
Epigenetic factors have been suggested as a potential explanation for disease discordance 
within identical twin pairs. In Study IV, we analysed DNA methylation in whole blood of 
708 twins with and without asthma using the Illumina 450k Beadchip. On the group level, 
340 CpG sites were significantly associated with current asthma at 9-14 years of age, but 
these associations were not replicated within asthma-discordant pairs. Confounding by 
genetic factors or cell type composition in the samples seemed to be of importance, and 
should be considered as influences of potential importance in future epigenetic studies. 
In conclusion, the work described in this thesis has combined the unique qualities of twin 
studies with data from population-based registers, interviews, and clinical examinations. The 
influences of transmitted (genetic) and acquired (twinship, early growth, and epigenetics) on 
childhood asthma were evaluated. From this selection, the transmitted factors proved to be of 
most importance to childhood asthma. 
SVENSK SAMMANFATTNING 
Hos barn såväl som ungdomar påverkas risken att utveckla astma av både arv och miljö. 
Eftersom tvillingar delar miljöfaktorer under uppväxten och en- och tvåäggstvillingar har 
olika stora delar av sin genetiska kod gemensam, så ger tvillingstudier unika möjligheter att 
studera samspelet mellan ärftliga och förvärvade riskfaktorer. 
Tvillingars astma i sig har dock varit ofullständigt studerad. Studie I syftade till att undersöka 
förekomsten av astma hos tvillingar jämfört med andra barn. Genom att länka data från 
Medicinska Födelseregistret, Patientregistret, och Läkemedelsregistret, kunde vi visa att 
tvillingar som grupp hade ökad risk att utveckla astma tidigt i livet, men inte efter sex års 
ålder. När resultaten korrigerades för att tvillingar ofta är födda tidigare och mindre än andra 
barn, så hade de istället lägre risk för astma. Att den förhöjda risken gick att förklara talar för 
att viktiga mekanismer för astma delas mellan tvillingar och andra barn. 
Låg födelsevikt och snabb tidig tillväxt har tidigare setts öka risken för astma. I studie II var 
syftet att studera tvillingars tidiga tillväxt och sambandet med astma. Baserat på längd- och 
viktuppgifter från barnhälsovårdsjournaler beskrev vi 2874 tvillingars tillväxt från 0 – 3 år. 
De tvillingar som senare utvecklade astma visade sig ha sin maximala tillväxthastighet 
förlagd lite senare jämfört med de tvillingar som inte fick astma. När resultatet justerades för  
födelsevikt – och därmed den föregående tillväxten under graviditeten – fanns inte längre 
något sådant samband.  
Astma och andra allergiska sjukdomar förekommer ofta tillsammans. I studie III ingick 
25306 tvillingar, varav knappt hälften hade lämnat salivprov för genetisk analys. Vi 
beräknade heritabiliteten – den del av variationen av en egenskap som beror på gener – och 
konstaterade att den låg runt 70-80% för både astma och annan allergi vid 9-12 års ålder. 
Baserat på salivproverna kunde vi bekräfta att sex stycken genvarianter som tidigare kopplats 
till astma hängde samman med astma också hos svenska barn. Däremot var det endast en av 
dessa gener (varianten rs3771180 i IL1RL1-genen) som var kopplad till någon annan fenotyp 
(hösnuva). 
I gränslandet mellan arv och miljö finns de epigenetiska faktorerna – som skulle kunna 
förklara hur enäggstvillingar, trots att de delar 100% av sina gener, ändå kan ha olika 
sjukdomar. I studie IV analyserade vi epigenetiska förändringar i blod hos 708 tvillingar med 
och utan astma. En del var diskordanta enäggstvillingar (den ena tvillingen i paret frisk, den 
andra sjuk). På gruppnivå hittade vi 340 olika epigenetiska varianter som var kopplade till 
astma – men det gick inte att se samma samband inom de diskordanta tvillingparen.  
I de studier som ingår i denna avhandling har en unik sammansättning av datakällor och 
metoder förts samman för att studera ärftliga (genetik) och förvärvade (tvillingskap, tillväxt 
och epigenetik) riskfaktorer. Bland de faktorer som studerats här verkar de genetiska – som 
överförs mellan generationer – ha störst inflytande över astma i barndomen.  
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1. FOREWORD 
 
While the purpose of a thesis summary is fairly clear –  to provide a context for and discuss 
the scientific work carried out by an individual over the course of a PhD education program –  
identifying the target audience is a more delicate matter. Many doctoral theses are only truly 
read by a handful of people (the PhD candidates themselves excluded – as the author of this 
work, I doubt I will ever  acquire a truly unbiased opinion of it) – which one might argue is a 
very anticlimactic outcome of all the effort it took to achieve it. I can, of course, not make 
anyone read this; nor would I truly wish for my words to be forced upon anyone. But I can 
aim to make it an enriching experience to try. 
On that note, I have tried to write a thesis in the spirit of open communication, honesty, and 
filled with the true enthusiasm I have felt while carrying out the work presented here. I hope 
it shows. And in that spirit – because science truly is fun – I hope that once you’ve read it, 
however small a part, if there are any questions or thoughts born in your mind as you do so 
that you will bring them to me. I’ll be there. 
Now: let’s talk science. 
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2. INTRODUCTION 
2.1 WHY STUDY ASTHMA? 
We live, in part, because we breathe. The art of respiration has been developed by evolution 
over millions of years.
1
 The human lungs, with their vast network of airways and alveoli, are 
ultimately a consequence of evolution and development; a biological machinery with the vital 
purpose of providing our bodies with the oxygen we infallibly need.
2
 Perhaps it is for this 
reason that respiratory diseases can be so utterly unsettling for those affected.  
Asthma affects hundreds of millions of people across the globe. The latest numbers from the 
World Health Organization, WHO, reveal an estimated total of 235 million people with 
asthma worldwide.
3
 A significant proportion of them are children; asthma is the most 
common non-communicable disease in this age group. As such, it is an important factor in 
worldwide childhood morbidity.
4,5
  
Yet despite the continued high prevalence of this disease
6
 and a substantial number of 
identified factors which are associated with an increased risk of asthma within a population,
7
 
piecing together these many different clues into a whole is an on-going challenge.  
Though one may find several pieces of a puzzle, identifying their proper place in the design is 
a challenge in itself. What this project aims to accomplish is not to finish the puzzle; I trust 
that it will continue to occupy my colleagues and myself for decades to come. The 
overarching aim for this thesis is to highlight a few particular features, in an attempt to shed 
new light on these well selected conundrums within the field. 
Before we get there, I will take you through a few concepts concerning epidemiological 
research in general, and genetic and early life epidemiology in particular. 
 
2.2 A NOTE ON DEFINITIONS 
The title of this thesis contains two keywords which merit clarification: transmitted and 
acquired. These are applied to concern specific elements hypothesised to be risk factors for 
childhood asthma. 
Within the scope of this thesis, transmitted risk factors are mainly the inheritable: specific 
genetic variants or heritability overall, as in Study III. Thus, the process of transmission 
considered here is primarily that which occurs between generations. 
Acquired risk factors refer to things a person may become exposed to or experience as a 
consequence of an environmental influence. In this work, the acquired risk factors discussed 
are infant growth (Study II) and epigenetic modifications (Study IV). It is also possible to 
view the epigenetic mechanisms as a bridge between the concepts of transmission and 
acquisition, in the sense that they act on the genetic factors but mediate environmental 
effects.
8
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Whether twinship (the exposure of interest in Study I) belongs in the transmitted or acquired 
category is less obvious. One might argue that as monozygotic (identical) twinning occurs 
after conception, it is acquired. On the other hand, dizygotic (fraternal) twinning, which 
happens when two zygotes are conceived at the same time, more commonly occurs in some 
families
9
 and could thus be considered a transmitted trait. While the experience of being a 
twin comes with particular features of intrauterine environment and the presence of a sibling 
of equal age, the acquired features of twinship may be of more importance. 
But the beauty of the thesis title does not lie in disentangling exactly which risk factor 
belongs where – rather in illustrating the position of the subject: balancing between the roles 
of genes and environment. 
2.3 EPIDEMIOLOGY AS A FIELD OF RESEARCH 
Epidemiology is the discipline of  medical science dedicated to the study of how a set of 
factors (often called exposures) are associated with a certain set of other factors (the 
outcomes). If people who have experienced the exposure on average more often get the 
outcome, we say that people with the exposure have an increased risk of developing this 
outcome. It is important to remember, however, that this is not an absolute.  
Indeed, on an individual level, interpreting a statement of risk tells you very little. The mere 
presence of a well known risk factor does not guarantee that a person will go on to develop 
the outcome – only that they are statistically more likely to do so compared to someone who 
is unexposed. As with everything else in life, the findings from new epidemiological studies 
should be viewed in balance with the already available information. For application in 
clinical settings, findings from observational studies hold a lower level of evidence compared 
to randomised clinical trials,
10
 but they are often an excellent starting point for answering 
questions arising in the clinic. Further, they may provide clues towards prevention of future 
cases of disease.  
However, for this purpose, the strength of the estimated association matters. Even a strong 
association in itself means little for the burden of disease in the population at large if the 
prevalence is low.  
Further, the fact that there is an association between an exposure and the outcome does not 
guarantee that the association was caused by the direct effect of the exposure on the outcome. 
Epidemiologists are ever concerned with avoiding the side effects of confounding – when a 
third factor associated both with the exposure and the outcome obscures the true relationship 
between the two, either making it seem as if there is one while there truly isn’t, or by hiding a 
true association.
11
 Additionally, if a study is cross-sectional – i.e. the exposure and outcome 
of interest have been measured at the same time – reverse causality, the possibility that it is 
the outcome that has caused the exposure and not the other way around, can sometimes not 
be excluded. 
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Finally, the results drawn from a study are only as good as the accuracy of measurement of 
the exposure and outcome will allow. Sometimes, observational studies are studies of the 
most suitable proxies of the true phenomenon. Measurement errors may arise when there is 
some disagreement – whether random or systematic – between what is measured and the true 
value.
12
 Additionally, information bias may result from misreporting of exposures or 
outcomes (such as by a disturbance in recollection of the exposure dependent on outcome 
status – referred to as recall bias13) and selection bias from performing a study within a group 
into which the exposure and outcome were factors in representation.
14,15
 All of these – and 
more – potential sources of errors and biases should be evaluated in the interpretation of 
results from epidemiological studies.  
Ultimately, while it is important to be aware of the general limitations of observational 
studies, they also have significant strengths. Some things cannot be randomised, and 
epidemiological studies – carried out within population-based registers or large well-
characterised cohorts – can provide uniquely powerful settings in which to apply intelligent 
designs to investigate the reality of the world that surrounds us.
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3. BACKGROUND 
3.1 ASTHMA AND ALLERGIC DISEASES 
3.1.1 What is asthma? Phenotypes, pathophysiology, treatment, and 
immunological aspects 
3.1.1.1 Asthma phenotypes 
While asthma is common during childhood, the characteristics of disease vary within this 
time span as well as between childhood and adulthood.
16
 Attempts have been made to 
describe these different expressions of the disease in terms of asthma and/or wheezing 
phenotypes. In 1995, one of the most widely acknowledged early attempts was made by 
Martinez.
17
 Since then, several attempts have been made to continue to build on either this or 
similar classification strategies.
18-24
 
Briefly, three different aspects are commonly considered in some way in most of these 
attempts: the age at which the disease is experienced, the trigger factors,
25,26
 and the disease 
severity.
27
 The age at which a child experiences asthma can be described in several different 
ways. One important dimension is the age of onset; conversely, it is also of interest until 
which age symptoms last.
23
 It is worth noting, however, that while there is a general 
agreement that some sub-classification of asthma is likely warranted, the possibility of 
making these distinctions within a given study depends on the level of detail in the collected 
information. From a clinical perspective, identifying factors that may lead to improved 
diagnostic methods or personalised treatment is probably of greatest interest.
28
  
A recurring argument within the field is whether the children who start wheezing at a very 
early age – many of whom do so in association with respiratory infections such as respiratory 
syncytial virus (RSV) or adenovirus infections – but cease to do so within a few years should 
be considered asthmatic. Today, many of them are referred to as ‘early transient wheezers’, 
and there is often discussion regarding whether to include these individuals within the asthma 
group in epidemiological studies, or to exclude them so as to retain the specificity of the 
outcome definition. Symptomatologically, all conditions that feature wheezing and 
obstruction among children lead to childhood respiratory morbidity, and may share common 
causes. Still, there has been some evidence that genetic variation differs between some early 
wheeze phenotypes,
29
 which would speak in favour of studying them separately to the largest 
extent possible. On the other hand, early wheezers who continue to wheeze until at least 18 
months of age may continue to show signs of airway inflammation – and, possibly, asthma – 
well into adolescence.
23
  
Due to the large overlap of respiratory symptoms, regardless of their persistence, it makes 
sense to still consider asthma as primarily one disease – but a heterogenous one. When 
translating results to clinical settings, the limitations of the phenotype definition under study 
should be acknowledged. 
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3.1.1.2 Pathophysiology and treatment 
Physiologically, asthma is characterised by hyper-reactivity in and inflammation of the 
airways. Hyper-reactivity leads to constriction of the airways in response to an irritating agent 
(such as allergens, cold air, and exposure to tobacco smoke) owing to contraction of smooth 
muscle cells within the bronchial wall. Additionally, secondary to the inflammation, there is 
often excess production of mucus within the airways of people with asthma.
30
 Alone or in 
synergy, these factors can result in bronchial obstruction and be very troublesome.
31
  
 
Figure 1 – Swedish treatment guidelines for continuous treatment of childhood asthma after 6 years 
of age. Adapted from the Swedish Paediatric Association, section for allergology 
(www.barnallergisektionen.se) 
Treatment of childhood asthma targets both of these dimensions. An overview of asthma 
symptoms and the Swedish Paediatric Association, section for allergology treatment ladder 
for different types of medication is presented in Figure 1, above. Swedish practice is in line 
with international recommendations.
32
 
Briefly, for sporadic or mild symptoms (Step 1), short-acting beta-2-agonists are prescribed 
and used primarily when the patient anticipates or has already developed symptoms. The 
purpose of this medication is to relax the overly constricted airways by selectively activating 
the beta-2-receptor (which mediates smooth muscle relaxation). Long-acting beta-2-agonists 
act according to the same principles, but are introduced at later treatment steps and always 
together with ICS (Step 3 and onwards). Long-acting beta-2-agonists are taken regularly and 
have longer half-life than short-acting beta-2-agonists. 
The chronic inflammation of the airways associated with asthma is treated with inhalations of 
corticosteroids (ICS). This is a standing prescription for many individuals with asthma, (Step 
2 and up). Many children only need to use ICS intermittently, such as when exposed to pollen 
and pets, during respiratory tract infections or conjunction with to exercise. Additionally, 
leukotriene receptor antagonists (LRTA) may be used as an alternative to ICS (Step 2), or as 
an addition to the aforementioned treatment regimen (Step 3 and 4).  
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3.1.1.3 Immunological aspects 
Asthma is both associated with and mediated by cells of the immune system. A key 
discussion has long been about the specificity of the T-cell response in the disease. Briefly, 
the adaptive immune system includes several cell types that mediate the acquired immunity 
of the host. The main cell family making up the adaptive immune system are the lymphocytes 
(a subset of leukocytes), which in turn can be divided into T, B and natural killer (NK) cells.
33
 
B cells produce antibodies, whereas T cells are the designated actors who clear out 
pathogens. NK cells are primarily associated with the innate immune response. 
Traditionally, T-helper cell responses have been seen as weighted in several disease 
patterns.
34
 For instance, in auto-immune diseases, where the immune system starts reacting 
against the body’s own cells, the response has long been characterised as Th-1-weighted. In 
contrast, in asthma and allergic diseases, where the pattern is instead characterised by an 
overreaction to external stimuli such as allergens or other irritants, the response has been seen 
as Th-2-dominant. Recently however these responses have proved to require more complex 
descriptions,
35,36
 and genetic variation along the T-helper cell pathway may be involved in 
disease susceptibility.
37
 
3.1.2 Comorbidity of asthma with hay fever, eczema, and food allergy 
Asthma displays significant comorbidity with several diseases within the allergic and atopic 
spectrum.
38-41
 The phenomenon called the “atopic march” gets its name from the idea that 
there is a natural progression of allergic diseases (primarily atopic eczema, asthma and hay 
fever) during childhood.
42-46
 In practice a child may develop these phenotypes in different 
orders,
47
 but comorbidity
38
 and IgE levels
48
 increase with age. Underlying this significant 
comorbidity, the predisposing risk factors may be shared (such as the large proportion of 
genetic components that are common to both asthma and hay fever
49
) or directly opposing. 
One example of the latter was shown in a pair of studies within the Swedish Twin Registry, 
in which low birth weight increased the risk of asthma,
50
 but high birth weight increased the 
risk of atopic eczema.
51
 Additionally, exposure to environmental tobacco smoke in the 
postnatal environment is associated with asthma, but less strongly associated with childhood 
eczema.
52
 Maternal smoking during pregnancy does not appear to be associated with 
eczema.
53
 This tendency for risk factors for asthma and allergic diseases to overlap, but also 
contain differences with respect to asthma vs. eczema or hay fever, continues in adulthood.
54
 
Comorbidity may also affect asthma symptoms. For example, children with some food 
allergies who also have asthma are at increased risk of hospitalisation and require more 
steroid treatment for their asthma.
55
  
Thus, comorbidity between asthma and allergic disease is both significant and of potential 
clinical consequence. The specific nature of shared risk factors for these diseases merits 
further investigation. 
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3.2 EARLY LIFE EPIDEMIOLOGY 
3.2.1 What happens in utero doesn’t stay in utero 
The hypothesis of developmental origins of health and diseases (DOHAD) was first discussed 
in the work of David Barker in the context of the effects of restricted foetal growth on adult 
cardiovascular health.
56,57
 Later, the hypothesis has been extended to the study of several 
other phenotypes, including respiratory diseases.
58
 In the case of asthma, the exact biological 
mechanisms by which conditions during foetal life may affect later respiratory health are not 
clearly established. There are however several established exposures originating during 
gestation that have effects on later health. These include restricted foetal growth,
50,59-64
  
premature birth,
61,65,66
 and intrauterine exposure to metabolites associated with maternal 
smoking during pregnancy.
67
 
3.2.2 Early life exposures and asthma 
Postnatal early life environment contains several different factors which have been 
hypothesised to affect asthma in childhood. Many of these supposed relationships have 
amounted conflicting evidence in their favour and have been the subject of much discussion 
within the scientific community. Some of the more stable associations have been a protective 
effect of belonging to a group of siblings
68,69
 and early exposure to animals,
70
 as well as 
increased risks of asthma associated with exposure to environmental tobacco smoke early in 
life
71
 and certain viral infections
72
 – although in the latter case reverse causality has been 
difficult to exclude. The same has been the case for early exposure to antibiotics, although 
much of the initially shown association between antibiotic exposure and asthma has recently 
been shown to have been due to familial confounding.
73
 Further, early growth and effects 
mediated via genetic and epigenetic mechanisms have been suggested to be of importance. 
These are described in the following sections. 
3.3 GROWTH AND ASTHMA 
Human growth is often described as divided into stages during which there are defining 
characteristics and features. But the borders between these stages are not as set in stone as 
they may seem – in reality, there is a continuum of changes and features may overlap. Still, 
the distinctions serve a purpose in illustrating some particularly important characteristics of 
each phase. 
3.3.1 Phases of early life growth 
Some of the most essential growth of our lives occurs in utero, where we transform from a 
single fertilised oocyte into a small human being of diverse cellular composition – within a 
matter of months. 
Intrauterine growth restriction (IUGR) may be caused by any number of factors, but usually 
results in a child being small for gestational age (SGA).
74
 This is principally different from a 
child who is born small because they were not carried to term. In other words, two infants of 
 11 
equally low birth weight may be small or appropriate for gestational age depending on the 
length of gestation – thus birth weight alone is not a sufficient proxy for SGA. In twin 
pregnancies, IUGR is more common than for singletons – but may affect only one of the 
twins.
75
 Previous studies of low birth weight and asthma have generally shown that low birth 
weight is associated with an increased risk of asthma in childhood.
50,59-64
 
Although exceedingly rapid growth in infancy may be considered an adverse growth pattern, 
the natural state of growth during the first two years of life is rapid in itself. Indeed, during 
the first year, a child is said to on average triple their weight.
76
 Still, children who are born 
with low birth weight or small for gestational age may experience a phenomenon referred to 
as catch-up.
77
 This type of growth pattern has been linked to obesity later in childhood, and 
some theorise that it may be associated with activation of inflammatory pathways.
78
 On the 
other hand, early rapid weight gain also occurs in infants who have not been born with low 
birth weight – although low birth weight is a strongly predisposing factor, feeding patterns 
and child’s gender are also of importance.79 Because it is possible that early infant growth 
occurring in response to an earlier restriction (catch-up) may be biologically different from 
differences occurring in response to current environment (such as would be the case with 
responses to feeding patterns or other modifiable factors), it may be valuable to distinguish 
between these two principally different patterns when it comes to their relation to childhood 
health outcomes. 
3.3.2 Previous studies of childhood growth and asthma as the outcome 
Initially, many studies of childhood growth and later or concurrent asthma did not study the 
growth process per se: rather, body mass index (BMI, kg/m
2
) was a commonly used 
exposure. Although this is a natural endpoint of childhood growth processes and may thus be 
considered a proxy of growth, several different growth patterns may result in the same value 
of BMI. 
Nevertheless, in terms of asthma, it was generally found that high childhood BMI held a 
positive association with disease.
80-88
 A major weakness of many of the BMI studies was that 
they were largely cross-sectional in nature – meaning it was not possible to exclude reverse 
causality.  
Soon, studies of BMI trajectories, or transitions between categories of BMI between 
different ages, became a new addition.
89-94
 These had the advantage of illustrating a direction 
of childhood growth between two or more time points, and were able to show that moving 
upwards in terms of BMI during childhood – or having a persistent high BMI – was 
associated with asthma. Early high BMI that later fell to normal levels did not seem to be 
associated with an increased risk.
89,90
 Similar patterns were later replicated in studies using 
latent growth mixture models
95
 and BMI gain Z scores.
96
 It may be important to keep in mind 
that changes in BMI during childhood may not be associated with asthma later in life.
97
 
Still, studies of BMI on its own could not capture nuances in growth that primarily occur in 
terms of changes in weight or height separately. Using longitudinally collected measures 
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from early childhood, other studies began to show that rapid increases in weight were 
associated with asthma or wheeze,
98-110
 and one study found that slow weight gain before 2 
years of age was protective against asthma symptoms.
111
 Concerning height gain, null 
associations
99,101,102,104,105,108,110
 were most commonly reported, although one study found a 
negative association between rapid height gain between 3-7 years and asthma at 8 years of 
age.
109
 Some studies applied more complex statistical models to describe specific features of 
growth patterns, rather than making calculations based on absolute increases or 
rates.
102,104,107,110,112
 Generally, significant differences concerned growth that occurred during 
the first year of life. 
But as outcomes of childhood growth
113-115
 and asthma
116
 are both highly dependent on 
genetic effects, it is possible that some of the aforementioned associations could be partially 
confounded by genetic factors. 
3.4 GENETIC AND EPIGENETIC EPIDEMIOLOGY 
3.4.1 The Human Genome: genetic and epigenetic variation 
A key principle to understanding deoxyribonucleic acid (DNA) structure is base pair 
combinations. The DNA backbone, the spine of the molecule, exists in 2 copies. Either of 
these can be used to re-create the other. This is due to the fact that DNA consists of a 
sequence of molecules: the nucleotides. These are adenosine (A), thymine (T), cytosine (C) 
and guanine (G).
117
 Due to the chemical structure of these bases, they can only be paired 
together in two ways within the DNA helix; A with T and C with G.  
The vast majority of the DNA sequence is identical within the human population. Yet in the 
half percent of the human genome that varies between individuals lies the key to our 
individuality.
118
 There are several different kinds of genetic variation, one of the most readily 
studied being the SNP: single nucleotide polymorphism.
119
 An SNP is a position within or 
near a gene in which different people have different alleles or genetic variants. At this 
position, some people may have one nucleotide, say A, but others another, say C. Due to the 
inheritance of one chromosome from each biological 
ancestor, a person may have different alleles of the 
same SNP on each chromosome.   
Epigenetic modifications are reversible molecular 
changes to the DNA molecule, which do not alter the 
genetic code; they do however affect its 
application.
120
 The most common type of epigenetic 
modification is DNA methylation, Figure 2. DNA 
methylation is performed by enzymes of the DNA 
methyl transferase family, which act to attach a 
methyl group (CH3- ) to cytosine (C).
121
 Figure 2  Chemical structure of a methylated cytosine 
molecule (5-Methylcytosine). The methyl group (-CH3) 
(orange) has been exchanged with a hydrogen 
molecule by the DNA methyltransferase enzyme. 
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DNA methylation most often occurs in connection to a so-called CpG site, which is any 
specific location along the DNA molecule where a cytosine base (C)  is immediately 
followed by guanine (G).
122
 Because DNA methylation occurs specifically at the CpG site, 
there needs to be a CpG site for it to occur at. Thus, individual genetic variation has at least 
one obvious association with whether a particular locus is methylated or not. This would be 
expected to have a certain impact on between-individual variation in DNA methylation,
123,124
 
but studies have also shown that there are more profound ways in which the gene sequence 
may influence the methylation patterns, which go beyond this.
125,126
 All of these mechanisms 
could be the underlying causes of so-called genetic confounding: the risk run by any study 
of epigenetic mechanisms which is carried out in a population of genetically unrelated 
individuals. Additionally, DNA methylation varies by cell type, and the tissue choice should 
be taken into account when interpreting results of DNA methylation analyses.
127
 
3.4.2 GWAS and EWAS 
Some of the first studies aiming to study genetic variation were so-called candidate gene 
studies.
128,129
 These studies specifically targeted genes which were either known to be 
involved in a particular pathway relevant to the disease, or otherwise hypothesised to be of 
importance for the phenotype in question, leading to disparate findings – many of which later 
proved difficult to replicate.
130,131
 One possible explanation for this is that the process of 
selecting an appropriate candidate gene propagates a bias based on the previous knowledge 
used to select it. 
Later, pre-designed assays testing a wide variety of loci at the same time were used. At first 
these chips were relatively small, testing a few tens of thousands of variants; later, they would 
test hundreds of thousands to millions of loci at the same time. Such studies are referred to as 
genome-wide association studies (GWAS).
132,133
 Although these approaches are often 
referred to as ‘hypothesis-free’, this is only true to the extent that scientists are looking for 
anything within this pre-defined subset of variability – a fishing expedition, to be sure, but in 
a pre-selected lake. As a result, different research groups have become accustomed to pooling 
their data (creating a sea out of the sum of several lakes, if you will) in large consortia. The 
results of these pooled analyses are often considered to be more reliable, as the power to 
detect even small associations becomes greater.
134
 A commonly used argument against these 
studies is the fact that heterogeneity in study designs may lead to a dilution or bias of the true 
results. 
The technology for detecting epigenetic variation has developed along many of the same 
pathways, but a few years later and at slightly more rapid pace (after all, it’s easier to copy an 
evolution of concepts than it is to invent it the first time around). Currently, we are in the era 
of EWAS – epigenome-wide association-studies and their subsequent consortia. As for 
GWAS, EWAS are now possible to perform using previously created arrays that test 
thousands of pre-defined loci at the same time. The Illumina 27k,
135
 450k
136,137
 and only 
recently 850k
138
 DNA methylation chips test methylation at tens to hundreds of thousands of 
CpG loci. This technology however comes with some limitations – of particular note is the 
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risk of batch effects.
139
 These occur when systematic differences in signal strength occur 
between sample plates or chips as an artefact of the method. To avoid a resulting bias, sample 
allocation within and between plates must be performed with care. 
3.4.3 Asthma and the genes 
Asthma is a highly heritable disease 
49,116,140-145
 but the specific features of this heredity – i.e. 
which genetic variants are primarily responsible – has been established mainly during the 
recent decade.
146-152
 There have been several large GWAS efforts in which asthma has been 
the phenotype of interest.
146-148,153-165
 Some of these have included both adults and 
children,
147,148,157,161,162,166
 or only one of these age groups.
153-155,158-160,163,164
 Due to the 
differences in asthma phenotype by age, there is a possibility that different genetic variants 
are of importance for asthma at different ages.
167
  
One of the most significant meta-analyses of asthma GWAS to date was carried out by the 
GABRIEL consortium and included data from over 20 materials, featuring both adult- and 
childhood-oriented cohorts.
146
 The results confirmed some but did not replicate all findings 
from previous studies (including both smaller GWAS and candidate gene studies). While it is 
possible that some of the failed replications were due to false positives in the original studies, 
the diversity of the definition of asthma diagnosis itself (one of the most common criticisms 
towards the GABRIEL consortium) could also be part of the explanation.
154
  
The numerous discovery efforts and their consecutive replication of some of each other’s 
results have resulted in clear indications regarding the importance of especially regions on 
Chromosome 2, 5, 6 and 17.
146,147,155,160,161,164
 For childhood asthma, the ORMDL3 (or 
gasdermin A / gasdermin B) locus on chromosome 17 featured particularly strong 
associations.
146,168
 Still, studies differ in terms of included age ranges, and different genetic 
variants may be of importance in other populations. It remains worthwhile to pursue targeted 
replication efforts within specific populations and age ranges, particularly in childhood. 
3.4.4 Asthma and the epigenome 
Epigenetic studies of asthma have also moved into the era of epigenome-wide array 
studies,
169-174
 but so far these present an inconclusive image. Results from collaborative 
consortia studies are – as of now – yet to be reported, and available studies have not disclosed 
the full results of their analyses. Within the top findings of statistical significance from these 
studies (including roughly 100 specific CpG loci),
169-174
 very few findings have been 
replicated. Specifically, these concern findings within the B2-adrenergic receptor gene 
(ADRB2)
169,175
 and the mitogen-activated protein kinases 6 and 7 (MAP3K6
171
 and 
MAP3K7
169
). Methylation in the ORMDL3 region may be associated with asthma control,
176
 
but the finding has not been replicated within discovery studies of asthma. In general, the 
overlap between findings in terms of genetic and epigenetic variance is limited. This speaks 
in favour of continuing the epigenome-wide approach, and also hints that the interplay 
between genes and environment may feature interactive effects between genomic regions.  
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As was the case with genetic variation, it’s possible that childhood asthma carries particular 
features also in terms of epigenetic variation. Additionally, genetic or cell type confounding 
has not previously been accounted for in most epigenetic studies of asthma: there are only 
two previous studies using twin designs.
172,177
  
3.5 WHY TWINS? 
3.5.1 Shared genes and environment – assumptions, advantages, and 
reasons for investigation 
For the genetic scientist, twins hold a special place of importance. The reason begins with the 
core of genetics: the DNA sequence, and the distinction between monozygotic (identical or 
MZ) twins and dizygotic (fraternal or DZ) twins. It is generally assumed that monozygotic 
twins share 100% of their DNA code and that DZ twins, like any other pair of full siblings 
share, on average, 50% of their segregating genes. As a result, MZ twins are always of the 
same biological sex, whereas DZ twins may be same-sexed (DZ-ss) or opposite-sexed (DZ-
os). It should be noted that this assumption is not necessarily 100% correct, as post-division 
point mutations
178
 or copy number variations (CNVs) within the genome may occur also 
within MZ twin pairs.
179
 However, recent studies indicate that such differences are rare.
180,181
 
Beyond the genetic, all twin pairs share their environment: both that in utero and, usually, the 
one in which they are raised. It is assumed that this sharing occurs to an equal extent across 
zygosities (also referred to as the equal environments assumption). But twin pregnancies 
are particular in the sense that they require two children to develop simultaneously in the 
womb. In practice, this may be associated with sharing both of the placenta 
(monochorionicity) and the amniotic sac (monoamniosity), depending on during which day 
of gestation twinning has occurred. Generally, these features are more common in 
pregnancies with MZ twins, but monochorionic DZ twins exist.
182
 Chorionicity may have a 
small effect on both birth weight
183
 and birth weight discordance within twin pairs.
184
 While 
the magnitude of the long-term impact of these intrauterine differences is largely unknown, 
their importance should be seen in relation to several other important features that twins are 
known to share, such as their age, siblings, parents, and usually home environment.   
Other specific features of twin pregnancies – such as on average shorter gestations and lower 
birth weights compared to singletons
185
 – holds potential importance for twin studies. When 
these factors are also associated with a phenotype under study, it may be of interest to 
investigate whether twins seem to differ from singletons in terms of this phenotype.
186
 
Together, the assumptions of shared genes and environment within twin pairs are the core of 
three methods applied within this thesis: heritability estimation (Study III), co-twin control 
analysis (Study II), and within-pair comparisons of DNA methylation (Study IV).  
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3.5.2 Heritability 
Heritability is a term for the proportion of the total variation of a disease or phenotype 
that is due to genetic factors. In twin models, heritability, also known as additive genetics, is 
usually symbolised by the factor A. Together with non-shared environment (E) and shared 
environment (C) or genetic dominance (D), it adds up to the sum of the total variation.
187
 
Figure 3 presents a simplified structural representation of such a model. 
Heritability estimates may differ between populations based on several different factors.
188
 
One explanation is if genetic 
factors are truly of different 
importance in these populations – 
but it could also be that the 
relative importance of 
environmental factors is 
different. One example might be 
if maternal smoking during 
pregnancy – which has been 
associated both with childhood 
asthma
189
 and early wheeze
190
 – 
is a bigger concern in one 
population versus another.  
In addition, heritability estimates 
may vary over time, between age 
groups,
191
 or for different 
phenotypes of the same disease. Adding to and updating available estimates of heritability 
can be a worthwhile effort that gives an indication of the current impact of genetic versus 
environmental factors for a phenotype and target group of interest. 
3.5.3 Within-pair and co-twin control analyses 
Whereas twin models are used to quantify the size of the total impact of genetic versus 
environmental factors on a phenotype, within-pair and co-twin control analyses are applied to 
a specific association between exposure and outcome.
187
 A prerequisite for both of these 
methods is that the included twin pairs are discordant (differ in their status of the trait within 
the pair) for both exposure and outcome – i.e. constitute informative pairs. Because this can 
be rare, within-pair analyses often include a relatively small number of individuals even when 
they originate from large twin cohorts. That said, these methods can present unique 
opportunities of discerning whether genetic or environmental confounding is of importance 
for the relationship under study – or highlight findings controlled for these factors. A further 
discussion of these methods is available in the Methods chapter, section 5.3.9. 
 
Figure 3 Structural representation of the ACE twin 
model, displaying the assumed correlations (boxes 
adjacent to the lines) between factors additive genetics 
(A), shared environment (C), and non-shared or unique 
environment (E) within a twin pair (Twin 1 and Twin 2). 
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4. AIMS 
 
The intent of this work is to study if and how a collection of transmitted and acquired factors 
influence childhood asthma. The thesis comprises four studies – their separate specific aims 
are as follows: 
To . . .  
1. Investigate the association between twinship and asthma, as well as to determine whether 
gestational age and birth weight mediates the potential association. (Study I) 
2. Test whether parameters of early growth were of importance for childhood asthma, and if 
genetic or familial confounding partially explains any such associations. (Study II) 
3. Present new heritability estimates of asthma, hay fever, eczema and food allergy in mid-
childhood. Secondly, to investigate whether genetic variants previously linked to childhood 
asthma are associated with this or related phenotypes in Swedish twins. (Study III) 
4. Compare DNA methylation in whole blood between twins with and without asthma, in the 
full STOPPA cohort as well as within asthma-discordant MZ and DZ twin pairs. Parallel 
analyses concern confounding by cell type. (Study IV) 
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5. METHODS 
5.1 DATA SOURCES 
Regularly recording and following up on statistics of the health of the Swedish population is 
one of the main activities of the National Board of Health and Welfare (Swedish: 
Socialstyrelsen).
192
 This serves both administrative and informative needs. For example, what 
later became the Medical Birth Register was originally started in response to a rise in 
congenital malformations that followed after pregnant women were prescribed the drug 
Neurosedyn (Thalidomide) during pregnancy.
193
 In addition to such population-based 
registers, cohort studies constitute another valuable source of information regarding public 
health. These cohort studies often originate from efforts of individual research groups or 
collaborations, and include targeted collection of data specifically for research purposes. 
Using the unique Swedish personal identification number (PIN), data from different sources 
may be linked together.
194
 This linkage allows for studies of intricate exposure–outcome 
relationships, with the potential to account for familial aggregation, socioeconomic status, 
and perinatal factors. It is important to note that although the resulting data can be extensive, 
it is only analysed in de-identified format. Individual researchers cannot connect the coded 
personal ID numbers created to the original PIN or identities of the study participants.  
This chapter introduces the 
population-based registers and 
cohorts featured within this thesis.  
5.1.1.1 The Swedish Twin 
Registry (STR) and 
relevant cohorts  
The Swedish Twin Registry 
(STR) is a collection of several 
age-based cohort studies.
195
 The 
relationships between the STR 
cohorts used in the work described 
in this thesis are  shown in Figure 
4. Further details regarding the 
cohorts are available below. 
5.1.1.2 The Child and Adolescent Twin 
Study in Sweden: CATSS-9/12 
Since 2004, twins born and living in 
Sweden are invited to the Child and 
Adolescent Twin Study in Sweden (CATSS) following their ninth birthday.
196
 During the 
first three years of data collection, the STR also invited twelve-year-old twins to CATSS. 
Figure 4  Relationship between the STR cohorts included in 
this thesis: CATSS-9/12, CATSS-15, CATSS-15/DOGSS, and 
STOPPA. 
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Twins born 1996 and onwards have always been nine years of age at inclusion in CATSS. 
The oldest twins in CATSS were born in 1992 – the youngest in 2007. 
Participation in CATSS starts with a telephone interview with the twins' parents. The 
extensive interview includes questions on child’s health, medication use, living situation, 
perinatal factors, and current weight and height, among other traits. A module including 
questions regarding the twin pair’s physical similarities is the basis for an algorithm-based 
assessment of zygosity. Later, twins have also been offered to determine their zygosity by 
DNA testing of saliva samples.
197
 To date, approximately n=28,800 twins have participated 
in CATSS-9/12.  
Study II, Study III and Study IV are all in some way connected to the CATSS-9/12 cohort, 
making it one of the most central data sources in this thesis. 
5.1.1.3 CATSS-15 , CATSS-15/DOGSS, and child growth records 
CATSS-15 and CATSS-15/DOGSS (Developmental Outcomes in a Genetic twin Study in 
Sweden) were both follow-up studies of CATSS-9/12 at 15 years of age.  
The main difference between the two studies concerns the invitation of study participants. 
The only requirement to be invited to CATSS-15 was to have qualified for an invitation to 
CATSS-9/12. To actually have participated was not a prerequisite. In contrast, twins invited 
to CATSS-15/DOGSS were selected based on screening for neurodevelopmental disorders in 
CATSS-9/12 using the Autism-tics, AD/HD and other comorbidities inventory (A-TAC) 
inventory.
198
 The full CATSS-15/DOGSS cohort also included co-twins of the screened twins 
(even if these had not screened positively themselves), as well as controls. 
Although CATSS-15/DOGSS also included a clinical examination with an in-depth 
evaluation of the neurodevelopmental disorders and psychiatric comorbidities, both the age 
15-follow up studies featured the same written questionnaire to twins and parents with 
questions on asthma, allergic diseases, weight, and height. Finally, this questionnaire also 
asked for twins’ consent to collection of growth data from their child and school health 
records. In this step there was some selection based on twins’ sex and self-reported BMI at 
age 15. This aspect has been further discussed in one of the publications related to this 
thesis.
199
 
Child health records are held at the child health care centres and include information on the 
child’s weight, height, administered vaccinations and developmental checkups.200 When the 
child starts school this practice is continued by the school health care system and documented 
in the school health record.
201
 Child health records are most often stored in county council 
archives in the child’s county of residence following the child’s transition to school health 
care. Thus, during collection of child growth data child health records were requested from 
county archives, whereas school health records were requested from high schools.  
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Consent for growth data collection was provided when the twins were 15 years of age, and 
the actual record collection proceeded afterwards. This collection included twins born 1993-
1996. The full growth data within CATSS-15 and CATSS-15/DOGSS includes n=3,172 
twins. 
Within this thesis, these cohorts were primarily the setting of Study II. 
5.1.1.4 STOPPA 
The Swedish Twin study on Prediction and Prevention of Asthma (STOPPA) includes 9- to 
14-year-old twins specifically selected from CATSS-9/12 based on their asthma status. The 
total number of twins who participated in STOPPA was 752. 
For STOPPA, the intention was to recruit a study population with three groups of 
approximately equal size. These were healthy concordant pairs (both twins in a pair had no 
history of asthma), asthma concordant pairs (both twins had a history of asthma), and asthma 
discordant pairs (one twin with and one without asthma). Each of the concordance groups 
included both DZ and MZ pairs.  
A publication describing the full data collection in STOPPA in detail is available.
202
 In brief, 
twins and parents were invited to one of seven clinical examination test sites (located in 
Stockholm, Gothenburg, Linköping, Lund, Lomma, Växjö, and Umeå). At the clinical 
examination, twins and parents each responded to written questionnaires. Twins also 
participated in clinical examinations (including lung function tests by spirometry and 
fractional exhaled nitric oxide) and provided biosamples. Blood, saliva, faecal and urine 
samples were all collected, some (faeces and urine) only in certain waves of the study. The 
blood sampling included two 4 ml EDTA tubes; one of these was stored at the KI Biobank 
for later DNA methylation analysis, and the other was sent to the clinical laboratory nearest to 
the test site for white blood cell count (WBC) measurements.  
The STOPPA cohort was the setting of Study IV. 
5.1.1.5 The Medical Birth Register (MBR) 
The Medical Birth Register (MBR) started in 1973 and covers 98% of all births in Sweden. 
The register includes information regarding maternal health indicators from antenatal care 
visits (height, weight, some diseases, and smoking during pregnancy), as well as information 
registered at child’s delivery (child's birth weight, gestational age, Apgar score, and mode of 
delivery, among other variables).
203
 Within the work of this thesis, the MBR was the source 
of covariates for Study I and Study II, and also where multiple births were identified in Study 
I. 
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5.1.1.6 The National Patient Register (NPR) 
The NPR covers all diagnoses given in in-patient care (from 1987 onwards) as well as those 
given in outpatient specialist clinics (from 2001 onwards). Visits to the emergency 
department in Swedish hospitals are not considered inpatient care unless the patient is later 
admitted.
204
 The NPR does not cover diagnoses given in primary health care.  
The diagnoses are recorded using the International Classification of Disease (ICD) system. In 
ICD version 10, diagnosis codes J45 and J46 are used for asthma; the corresponding code in 
the previous ICD version 9 is 493. Along with the diagnosis code, the dates of admittance, 
diagnosis, and discharge from the hospital are also recorded. Either of these can then be used 
as the date of diagnosis depending on one’s preferences and the research question at hand. In 
many cases, the dates overlap.  
Data from the NPR were used to construct outcome variables in Study I, Study II, and Study  
III. 
5.1.1.7 The Swedish Prescribed Drug Register (SPDR) 
The Swedish Prescribed Drug Register (SPDR) started on 1 July 2005. It contains 
information on all prescription medications dispensed to the Swedish population. Each 
observation in the register reveals the date of prescription, date of dispensing, and the 
Anatomic Therapeutic Chemical (ATC) code of the medication prescribed.
205
 Most 
medications used to treat and manage asthma are sorted under ATC code R03 (obstructive 
lung diseases). The R03 group is further classified into the chemical subgroups.
206
 The full 
list of medication dispenses used to construct the asthma outcomes within this thesis can be 
seen in Table 1. 
An inherent weakness in the SPDR is the inability to distinguish between dispensed and 
actually ingested medications. However, if a person continues to return to the pharmacy and 
fills a similar prescription several times, it becomes more likely that it has also been used.  
Also, there can be questions regarding whether the medication is used for the disease 
intended to be studied – the validity and specificity of different medications may vary 
between diseases. For asthma, this point is of particular interest as there are other conditions 
with wheezing with which it may be confused. Therefore, there have been efforts to construct 
combinations of outcomes that are validated to better correspond to an actual asthma 
diagnosis.
207
 These outcomes can then be used on their own or as a complement to asthma 
diagnosis from the National Patient Register.  
Data from the SPDR were used to construct outcome variables in Study I, Study II, and Study 
III. 
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Table 1. List of medications the dispensing of which (as registered in the SPDR) was used to construct 
the validated asthma medication outcomes. Brand names extracted from fass.se. 
ATC 
code Group name 
Active substances 
included Sold in Sweden as… 
R03AC 
Selective beta-
2-agonists  
Salbutamol 
Airomir, Airomir Autohaler, Airsalb, Buventol 
Easyhaler, Salbutamol Arrow, Ventilastin 
Novolizer, Ventoline, Ventoline Diskus, 
Ventoline Evohaler 
Terbutalin Bricanyl, Bricanyl Turbuhaler 
Salmeterol Serevent Diskus, Serevent Evohaler 
Formoterol Formartris Novolizer, Oxis Turbuhaler 
Indacaterol Onbrez Breezhaler 
Olodaterol Striverdi Respimat 
R03BA 
Inhaled 
corticosteroids 
(ICS) 
Beclomethasone 
AeroBec, AeroBec Autohaler, Beclomet 
Easyhaler 
Budesonide 
Budesonid Arrow, Budesonide Teva Pharma, 
Giona Easyhaler, Novopulmon Novolizer, 
Pulmicort, Pulmicort Turbuhaler 
Fluticasone 
Fluticasone Cipla, Flutide Diskus, Flutide 
Evohaler 
Momentason Asmanex Twisthaler 
Ciclesonide Alvesco 
R03AK 
Fixed 
combinations 
of beta-2-
agonist and ICS 
Salmeterol + 
Fluticasone 
Airflusal Forspiro, Salmeterol/Fluticasone Cipla, 
Seretide Diskus, Seretid Evohaler 
Formoterol + 
Budesonide 
Bufomix Easyhaler, DuoResp Spiromax, 
Sybmicort Turbuhaler 
Formoterol + 
Beclomethasone 
Innovair 
Vilanterol + 
Fluticasone furoate 
Relvar Ellipta 
Formoterol + 
Fluticasone 
Flutiform 
R03DC 
Leukotriene 
receptor 
antagonist 
(LRTA) 
Montelukast Montelukast, Singulair 
 
5.2 STUDY POPULATIONS AND DESIGNS 
5.2.1 Defining asthma 
There are several different ways to identify asthma cases. The main difference between the 
clinical situation and research is that in the first, the examiner has direct access to the patient. 
In research, this is not always the case. Without the clinical examiner's possibilities to ask 
clarifying follow-up questions, perform tests first-hand, or request consultations from 
colleagues, the researcher needs to rely on the reports of others. The following section 
describes a few ways asthma may be defined under these circumstances. 
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5.2.1.1 Register-based methods of identifying asthma cases (Study I, II, and III) 
In Sweden, the population-based clinical registers of medication dispensing (SPDR) and 
diagnoses (NPR) are highly useful as proxies for the medical researcher. Still, using these 
registers requires some qualified data mining. To make the most of the data, the sources 
should be used to complement each other. 
A main issue with the SPDR is that the same medication may be prescribed for different 
diseases. Simply by looking at one filled prescription we may not be able to identify which. 
The beta-agonists prescribed may just as well be intended as temporary relief during a severe 
respiratory infection in an otherwise healthy individual as for someone with an asthma 
diagnosis. 
Conversely, using a purely-register based definition of asthma diagnosis is limited by the fact 
that, as stated previously, the NPR only covers inpatient care. The asthma diagnoses recorded 
in this register will be the more severe 
cases; the less severe cases may be 
handled entirely in primary care. 
And this is where the beauty of combining 
the data sources comes into play. The 
SPDR covers all prescriptions filled 
outside hospitals – also those prescribed 
by primary care physicians. Using both 
data sources thus allows us to capture 
some cases that would otherwise be 
missed.  
To circumvent this problem of dispensed 
medication being misclassified, a 
validation study was performed by 
Örtqvist et al and published in 2013.
207
 In 
the validation study, medical records of 
individuals fulfilling predefined asthma 
medication criteria were requested from 
primary care clinics and hospitals all over 
Sweden. The record entry from the day of 
prescription was reviewed to see whether 
the individual also fulfilled asthma 
diagnosis criteria. In this manner, two different medication outcomes were defined, which 
both had high positive predictive value (PPV) for clinically diagnosed asthma. The two 
asthma medication outcomes are defined in Figure 5. They were usually used in combination 
(i.e. fulfilling either of the two definitions was sufficient). 
Figure 5 Definitions of the validated asthma medication 
outcome combinations from Örtqvist et al.
207 
ICS = inhaled corticosteroids ẞ2 + ICS = fixed 
combination of selective beta-2-agonists and ICS. LTRA 
= Leukotriene Receptor Antagonists. ẞ2 = Selective 
beta-2-agonist only.  
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The validation study also showed that on their own, the medication outcomes were more 
accurate after than before 4.5 years of age. Therefore, in Study I we also performed sensitivity 
analyses using a combined outcome where both asthma medication and a register diagnosis 
were required. 
5.2.1.2 Questionnaire-based assessment (Study II, III, and IV) 
Finally, one can obviously ask the study participants themselves whether they have asthma or 
not. Or, in the case of studies of children, one usually asks their parents. This was the case in 
Study III and Study IV, where parental telephone interview (Study III) or questionnaire (Study 
IV) was used as a source of information on child’s asthma ever (Study III) or currently (Study 
IV). Study II featured questionnaires to both twins and parents, and although these did not 
always agree we opted to include as cases all twins for whom asthma had been reported, 
regardless of who reported it. 
5.2.2 Overview of Study I 
5.2.2.1 Study population 
The study population in Study I was identified through the MBR and divided into two groups 
of children: one ‘older’ and one ‘younger’ group. The older group was born between 1 
January 1993 and 1 June 2001. The younger group was born between 1 July 2005 and 31 
December 2009. 
Cut-offs in terms of birth dates were determined on the basis of ensuring coverage of the 
study participants in the SPDR. For the older group, we intended to ensure that each study 
participant had at least 5 years of data available before their 18th birthday. In the younger 
group, we aimed to include all individuals who had data in the SPDR from birth, and who 
were then covered in that register for at least one year onwards (so as to allow them to fulfil 
medication outcome B during this time). 
5.2.2.2 Study design 
Study I is a population-based register study of all twin and singleton children born in Sweden 
between the aforementioned dates. Due to the different setups in the two cohorts, different 
analysis methods were used.  
In the younger cohort, with complete coverage in both outcome data sources from birth, we 
were able to detect the first time they experienced any of the outcomes. Knowing the date of 
this event enabled us to use survival analysis (Cox Proportional Hazards Regression) in this 
group.  
In the older cohort, the two outcome data sources covered slightly different points in time, 
and most of the participants were not covered in the SPDR from birth (the youngest 
participants in the older cohort were just above 4 years of age when it started). Therefore, 
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analyses based on the prevalence of asthma across all the covered time were deemed 
preferable. Logistic regression was used in this group. 
5.2.2.3 Exposure and outcome definitions 
Twinship was the exposure and childhood asthma (as defined by medication, diagnosis, or 
both) was the outcome. In the older group, information on dispensed medication and asthma 
diagnoses before 5 or after 18 years of age was not included. 
5.2.2.4 Notes on measurement methods in Study I 
Multiple birth status in the MBR 
The MBR contains information on whether a birth is singleton or multiple, but as triplet and 
higher order multiple births are also included in this variable these had to be manually 
counted and excluded. This was done by summing the number of births to the same mother 
within +/-1 days of the ‘index’ child’s birth (to allow for the possibility of multiple birth 
siblings being born on different sides of midnight). If this number equalled 3 or higher, the 
children were not eligible for the study and all observations in this higher order multiple 
group were dropped.  
Mode of delivery 
We considered this an interesting potential confounding factor for Study I as twins are more 
often delivered by caesarean section, and there has been a debate in the literature regarding 
whether C-sections increase the risk of asthma.
208
 As elective caesarean sections are on the 
rise for various reasons,
209
 they are becoming more common also for singleton deliveries.  
Using the same categorisation as in a previous Swedish study that was based on similar 
data,
208
 we were able to some degree to distinguish between elective (planned) and 
emergency caesarean sections – which is of interest as previous studies have indicated that 
these different indications for the same delivery method may be associated with different 
childhood asthma risk patterns. 
5.2.3 Overview of Study II 
5.2.3.1 Study population 
For Study II, we selected all study participants in either CATSS-15 or CATSS-15/DOGSS for 
whom childhood growth (weight or height) data from 0-3 years of age had been successfully 
collected. This resulted in a study population including n=2,874 twins. 
5.2.3.2 Study design 
The exposure data were longitudinally recorded at child health care centres prior to the study 
initiation. The individual CATSS cohorts can be described as retrospective studies, but the 
fact that there are several follow-ups at various ages adds a longitudinal dimension. 
Additionally, the CATSS study participants have been linked to several population-based 
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registers, including the NPR and SPDR – the coverage of which sometimes exceed the time 
period covered by the questionnaires themselves. 
5.2.3.3 Exposure and outcome definitions 
For weight and height separately, childhood growth parameters were modelled using 
SuperImposition by Translation and Rotation (SITAR; further explained in section 5.3.6, 
Growth modelling).
210
 Each SITAR model parameter (a, size; b, tempo; and c, velocity) for 
each growth dimension was used as its own separate exposure in a logistic regression model.  
As the study used data from CATSS-15 and CATSS-15/DOGSS, data from CATSS-9/12 
were also available for many of the study participants. The asthma outcome was constructed 
as asthma according to reports by either the twin or a parent in any of the STR 
interviews/questionnaires, or as identified from the NPR or SPDR before age 18. Finally, in 
an additional analysis, this asthma was divided into disease that first occurred before or after 
3 years of age. 
5.2.3.4 Notes on measurement methods in Study II 
Childhood growth data 
In Study II, weight and height measurements from birth up to 3 years of age were recorded in 
childhood health records: routinely kept medical records that are established for each child 
once they enter child health care. Initially, the child is measured lying down on a scale. At 
around two years of age, the child starts to be measured standing up.
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 Once measured, the 
age at or date of measurement is noted in the child health record. In the present day, when 
most records are digitally kept, the growth curve for the child is then plotted automatically. In 
the 1990s, when the participants of Study II were born, however, plotting was performed 
manually by the school health nurse. We used the exact date of measurement to calculate the 
age whenever possible, but sometimes had to substitute a missing value by reading off the 
child’s growth curve. This of course introduces a potential for human error; however, as those 
extracting data from the child health records did not have access to information on the asthma 
outcome, these reading errors should be spread out evenly between the groups (non-
differential misclassification).  
5.2.4 Overview of Study III 
5.2.4.1 Study population 
Study III included all twins who were responders in CATSS-9/12 as of October 2014, 
n=25,306. A subset of these twins (n=10,075) had been genotyped (see details on page 28) 
and data on 16 SNPs previously associated with childhood asthma were available. 
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5.2.4.2 Study design 
Study III combined two main study designs: a quantitative genetic study of the heritability of 
asthma and related phenotypes, and a genetic association study of 16 SNPs and these same 
phenotypes. 
5.2.4.3 Exposure and outcome definitions 
Study III deals with phenotypes (asthma and commonly comorbid allergic diseases: these 
were hay fever, atopic eczema, and food allergy) and genetic exposures (either known single-
nucleotide polymorphisms, SNPs, or the more abstract heritability concept).  
The phenotypes were defined as follows: 
1) asthma was defined based on a combination of different data sources; these were the 
CATSS-9/12 telephone interview, the SPDR and the NPR. Any asthma was defined as 
having asthma according to any of these data sources. Each data source was also used to 
construct its own outcome.  
2) wheezing was from CATSS-9/12, and is here to be seen primarily as a complement to 
asthma. Due to the design of the telephone interview, the question regarding wheezing was 
only asked when the prior question (about asthma ever) had been answered in the negative. 
Thus, this was only such wheezing that had not already been classified as or later developed 
into asthma by age 9 or 12. Likely, this is a particular phenotype (including the so-called 
early transient wheezers) but which differs somewhat from many other studies where 
wheezing has been independently assessed. 
Based on additional information regarding symptom duration, wheezing was further 
classified into that which occurred ever or lasted until after three years of age – a distinction 
intended to at least in part distill out the early transient wheezers. 
3) hay fever, food allergy, and atopic eczema were based on parental reports in CATSS-
9/12. 
5.2.4.4 Notes on measurement methods in Study III 
Zygosity 
The most important purpose of zygosity testing is to distinguish between genetically identical 
(MZ) and same-sexed non-identical (DZ) twins. Opposite-sexed twin pairs are always DZ. 
There are two primary sources of zygosity assessment in CATSS: a question-based algorithm 
based on perceived physical similarity between the twins
195
 and DNA testing of both twins 
using an array featuring 46 predetermined SNPs.
197
 Each method has been validated with 
>95% accuracy. When available, DNA-based zygosity assessment took precedence over that 
based solely on the algorithm. In the Study III study population, 58% of twins (n=14,608) had 
their zygosity assessed by the algorithm, and 41% (n=10,398) by DNA.  
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Genotyping 
For the purposes of this study, 18 SNPs were selected to be genotyped. However, only 16 of 
these SNPs were successfully genotyped. A full list of the genotyped SNPs is available in 
Table 2, below. The two SNPs which could not be genotyped were both located in the HLA 
region on Chromosome 9, and were previously associated with asthma
146
 or total serum IgE 
levels.
212
 Genotyping was performed at KBioscience in Hoddesdon, Herts, UK. 
 
Table 2 List of SNPs that were selected for genotyping in Study III, by chromosome (Chr), closest 
gene, position in relation to said gene, SNP name, minor allele, and the discovery study from which 
the SNP was identified.   
Chr Gene Location SNP 
Minor 
allele 
Source 
1 IL6R Intron rs4129267 T Ferreira et al 2011
148
 
2 IL1RL1 Intron rs3771180 T Torgerson et al 2011
147
 
2 IL18R1 Intron rs3771166 A Moffatt et al 2010
146
 
5 TSLP Nearby region rs1837253 T Torgerson et al 2011
147
 
5 SLC22A5 Intron rs2073643 T Moffatt et al 2010
146
 
5 IL13 Intron rs1295686 T Moffatt et al 2010
146
 
6 HLA-DQB1 Nearby region rs9273349 
Genotyping 
failed 
Moffatt et al 2010
146
 
6 HLA-DQB1 Nearby region rs9469220 
Genotyping 
failed 
Levin et al 2013
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9 IL33 Nearby region rs1342326 C Moffatt et al 2010
146
 
9 IL33 Nearby region rs2381416 C Torgerson et al 2011
147
 
15 RORA Intron rs11071559 T Moffatt et al 2010
146
 
15 SMAD3 Intron rs744910 A Moffatt et al 2010
146
 
17 Z2BP2 Intron rs12936231 C Verlaan et al 2009
151
 
17 GSDMB Exon rs2305480 A Moffatt et al 2010
146
 
17 GSDMB Intron rs11078927 T Torgerson et al 2011
147
 
17 GSDMB Intron rs7216389 T Moffatt et al 2010
146
 
17 GSDMA Exon rs3894194 A Moffatt et al 2010
146
 
22 IL2RB Intron rs2284033 A Moffatt et al 2010
146
 
 
Although only 10,075 twins had been genotyped themselves, due to the fact that some of 
these were MZ the SNP values for the same genotypes in their non-genotyped MZ co-twins 
could be imputed. Following this imputation, 12,388 twins had genotype data. 
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As retaining both twins from an MZ twin pair in genetic association analysis would have 
inflated the estimates, we randomly selected one MZ twin from each pair to keep in the 
statistical analysis. This could be either the twin whose DNA was originally analysed, or the 
co-twin whose genotype was imputed based on the first twin’s sample. 
5.2.5 Overview of Study IV 
5.2.5.1 Study population 
The study population in Study IV consisted of all twins in STOPPA who had contributed at 
least one whole blood sample that could be used for DNA methylation analysis. The total 
number was 708 twins (94% of the total study population in STOPPA).   
5.2.5.2 Study design 
Study IV is a cross-sectional cohort study featuring detailed clinical examination focused on 
childhood asthma. 
5.2.5.3 Exposure and outcome definitions 
DNA methylation at ~485,000 CpG sites was measured using the Illumina 
HumanMethylation450 BeadChip (Illumina 450k).
137
 For the primary analyses, current, 
parent-reported asthma at the time of the clinical examination was used. This meant that some 
twin pairs were re-classified following the selection to the STOPPA cohort, as they had 
received an asthma diagnosis between the time of the participation in CATSS-9/12 and the 
later clinical examination in STOPPA. 
5.2.5.4 Notes on measurement methods in Study IV 
DNA collection, storage, and extraction 
Blood samples to be used for later DNA methylation analysis were collected in 4 ml EDTA 
test tubes at the STOPPA test centres. To ensure that these samples were acquired from as 
many twins as possible, they were usually the first samples to be taken. After clinical 
examination, samples were stored at -20 degrees Celsius during transport to their long-term 
storage location (usually arriving within the next two days), after which they were kept in 
freezers at -80 degrees Celsius until the point in time at which they were analysed. All DNA 
was extracted at the KI Biobank using the Chemagic STAR DNA Blood 400 kit. 
DNA methylation analysis and plate layout 
DNA methylation analysis was performed at  the Mutation Analysis Facility (MAF) at 
Karolinska Institutet Campus Huddinge. Sample plates contained 96 wells spread over 8 
chips featuring 12 samples each in a predetermined plate layout. This plate layout was 
designed to minimise the risk of results being affected by so-called batch effects, which are 
systematic errors that may arise in this type of laboratory analysis.
213
 Within each 96-well-
plate, 5 control samples were included. These control samples included one test sample of 
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known methylation pattern (ZYMO-1331), one sample with high methylation (ZYMO-high), 
one sample with low methylation (ZYMO-low), and two samples that were copies of real test 
subject samples from the same plate. Apart from the fact that none of the control samples 
should occupy the top right sample well, they could be randomly allocated anywhere on the 
plate. The remaining 91 wells could be used for study subject samples. The position of all test 
subject samples was randomised across plates and chips to the highest degree possible. 
However, as our core comparison in the study is the within-pair analysis in (discordant) twin 
pairs,
214
 we elected to keep twin pairs’ samples together within the same chip.  
Because not all twin pairs both 
contributed blood to the study even 
though they otherwise took part in 
the clinical examination, there were 
32 ‘single’ twins whose samples 
were used to balance out uneven 
numbers (resulting from the fact 
that there was an uneven number of 
control samples to be included). A 
figure illustrating one of the 
potential results of this plate layout 
system (specifically, the plate 
layout of plate 7) is shown in 
Figure 6. 
White blood cell (WBC) counts  
White blood cells (WBC), or leukocytes, are one of the primary cell types circulating in the 
blood. They are also the only blood cells to carry DNA. Thus, in any given sample, the DNA 
methylation patterns represented will primarily be those of the leukocytes.  
In STOPPA, WBC counts were analysed at local laboratories close to the clinical test centres. 
The second 4 ml EDTA sample was used for this purpose.
202
 The WBC counts are made up 
of a total leukocyte count, as well as the number of cells of each subtype. The primary 
subtypes were the granulocytes (neutrophils, eosinophils, and basophils) and lymphocytes 
(including T- and B-cells). Granulocytes were further divided into neutrophils, eosinophils, 
and basophils.
33
 Basophils are very few in number. Neutrophils and eosinophils, on the other 
hand, are numerous, and levels may vary with disease, including asthma.
215
 When this occurs 
to such a degree that the cell type becomes over- or under-represented in a blood sample, it 
could affect the DNA methylation pattern in the sample.
127
 This will be referred to as 
confounding by cell type, i.e. that differential DNA methylation detected in the sample is 
that of a specific cell type and not necessarily something specific to the disease itself. 
Figure 6 Plate layout of plate 7 in the DNA methylation analysis in 
STOPPA.  
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5.3 STATISTICAL METHODS 
5.3.1 The nature of statistics 
Briefly, statistical analysis in epidemiology is intended to describe the relationship between 
an exposure (something an individual is, does, or has been exposed to – often referred to as a 
potential risk or protective factor) and an outcome (usually a trait or disease, such as asthma). 
This is done by collecting a set of data on both exposure and outcome in a number of 
individuals, and thereafter making calculations based on these data or imposing a statistical 
model on them. Then, conclusions are made based on the patterns of associations found 
within the results of these calculations. 
The choice of model or calculation performed depends on several factors; whether the 
exposure and/or outcome is continuous or categorical, if they vary over time, if some 
individuals do not have all the data, and how the variable is distributed within the population 
all come into play. A common basic prerequisite for many statistical models is that the 
observations are completely independent from each other. This is violated in twin and family 
studies. In these, this problem needs to be circumvented  by somehow accounting for the 
clustering of observations within specified groups (i.e. families). On the other hand, other 
types of models rely on these correlations to draw specific conclusions about genetic and 
environmental components. 
The following section introduces the statistical models and analytical methods applied within 
the work of this thesis. First, however – a note on association versus causation. 
5.3.2 Association is not causation – the benefits of Directed Acyclic Graphs 
Directed acyclic graphs – or DAGs – are a helpful tool to visualise the supposed relationships 
between an exposure, an outcome, and various other factors which may be connected to these 
variables of interest.
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 The primary purpose of this visualisation is two-fold: to increase the 
clarity of communication regarding the exposure–outcome association that is in fact under 
study, and to ensure that no extraneous factors irrelevant to the relationship at the heart of the 
question are allowed to intrude in the model. When such intrusion happens, it may be harmful 
not only because it risks weakening the statistical power, but because adjusting for some of 
these factors (so-called colliders – more on these later) may introduce bias. 
DAGs (of which Figure 7 presents an example, which serves to illustrate the concepts 
outlined in the current and following section) imply some assumptions and basic 
requirements. The arrows imply not only an association, but also state the direction: thus 
saying that it is variable A that affects variable Y and not the other way around. Unless the 
researcher has a clear idea about the explanation for the potential association between A and 
Y, this direction may actually be somewhat difficult to determine. 
In addition to deciding on the direction of an arrow, one also needs to decide whether it's 
supposed to be there in the first place. Omitting to draw an arrow between two factors in a 
DAG (such as between X and L in the example) is a strong statement, as it means the person 
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who constructed the DAG has strong reasons to believe there is in fact no direct connection 
between these two factors. 
5.3.3 Confounders, colliders, and mediators 
The construction and display of a DAG may be a helpful exercise in itself. But the next step 
is when one can unleash its true power: that of discerning which factors acting in the vicinity 
of an exposure and outcome are the potential confounders
217
 that should be adjusted for, 
mediators that may account for part of the effect between the exposure and the outcome, or 
colliders that if controlled for may lead to biased results.
218
 
 
Figure 7 An example DAG. A is the exposure, Y is the outcome, X is a mediator between A and Y 
(accounting for some of the total effect), U is a confounder, and L is a collider. The orange arrow   
A->Y represents the direct effect of A on Y. The total effect of A on Y goes through the pathways A -> 
Y and A -> X -> Y. 
An association between an exposure and an outcome, provided that it exists, is sometimes 
made up of a sum of different effects. There is always a total effect: this is the association 
seen if one estimates the association between A and Y without accounting for any potential 
confounding whatsoever. Then there is the direct effect: the part of the association that is 
purely due to A and Y, without going through any factors in between. And finally, there is the 
potential for mediated effects: that A acts on Y through another factor X. The total effect of 
A on Y is the sum of the direct and any mediated effects. 
If the direct effect is the association of interest, any potential backdoor pathways between A 
and Y must be closed.
219
 In this example, this would be accomplished by conditioning the 
analysis on X (the mediator) and U (the confounder). However, umeasurable or unknown 
confounding may remain. 
5.3.4 Logistic regression (Study I, II, and III) 
Used in Study I, Study II, and Study III, logistic regression models were perhaps the most 
prevalent statistical analysis methods applied within this thesis. They are a good fit in many 
studies and for many types of data (so long as the outcome under study is categorical and 
binary, for instance asthma yes (=1) or no (=0)). Another assumption of the logistic 
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regression model is that the observations within the data set should be unrelated to each other 
– this includes the exposure variables included in the model. If not, clustering or interaction 
may need to be considered. This was the case with sibling constellations (Study I) as well as 
twin pairs (Study II and Study III). 
The effect estimate of logistic regression models is the odds ratio (OR), usually presented 
together with a 95% confidence interval (CI). Clustering within pairs or groups is often 
accounted for by calculating robust standard errors using a clustered sandwich estimator, 
which in turn widens the confidence intervals.
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5.3.5 Cox Proportional Hazards Regression (Study I) 
Cox Proportional Hazards Regression is a form of survival analysis that was used in Study I. 
Briefly, survival analysis presents the effect estimate as a hazard rate: the number of events 
occurring at the time t, in which the denominator is the number of remaining individuals who 
have yet to experience the event. In Study I, attained age was the underlying time scale. The 
possible endpoints of the study were: attaining the outcome (for asthma medication, the date 
of the first dispensing of any prescription in a medication combination that fulfilled the 
outcome was used as the event date), death, and migration (i.e. leaving Sweden and thus no 
longer being covered by the population-based registers). 
The proportional hazards assumption states that the relative difference (hazard ratio) 
should be constant between exposed and unexposed groups over time.
221
 In each case of 
analysis, it should be examined whether this is true. Such examination can be performed  
either by inspecting a curve and performing a visual assessment, or by testing in post-
estimation following the execution of a model. When the proportional hazards test fails, 
separate effect estimates may need to be presented for different age groups. This was the case 
in Study I, where the results in the younger cohort were presented over different time intervals 
(0-1.5 and 1.5-5.9 years of age). 
5.3.6 Growth modelling (Study II) 
For Study II, we used the SITAR – SuperImposition by Translation and Rotation – growth 
model. SITAR produces three parameters for each individual: a (size), b (tempo) and c 
(velocity).
210
 Each of these describes individual growth of each child as it compared to the 
average curve in the whole population, and can be applied to either weight or height 
change.
222
  
The basic structure of a fitted population growth curve resulting from this model is shown in 
Figure 8. The x axis is usually a time scale: in this study, we had access to the exact date of 
most measurements, and could therefore calculate the age in years down to decimals. The y 
axis is the growth measurement, in this example: weight in kilograms (kgs).  
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Figure 8 Fitted population growth curve from a SITAR model (black line) in Study II. The light grey 
and magenta lines illustrate the potential effects of positive shifts in the a or b parameter. 
The interpretation of the individual growth parameters in this context is as follows.  
a (size) represents the shift of the individual’s growth curve on the y axis; in other words, 
how large the individual is compared to the general study population. A positive value of a 
represents a larger size than the average, whereas a negative value is a smaller size. The unit 
of measurement of the a parameter is the same as the y axis: here, it would be kgs. 
b (tempo) describes the timing of the maximum growth velocity; whether an individual has 
their ‘growth spurt’ (provided a classical such exists within the time window of interest – if 
not, it will simply be point at which the most rapid growth within the interval takes place) 
before (negative value of b) or after (positive value of b) the population average. It is thus a 
shift of the growth curve along the x axis. 
Finally, the c (velocity) parameter is the natural log of a multiplier of the slope of the growth 
curve compared to the population average. Those with a positive c have had steeper growth 
than the population average. 
By nature of the character of growth during different points of time in childhood, the SITAR 
parameters are correlated. Therefore, once estimated, the growth parameters were included as 
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exposures in their own separate logistic regression model (i.e. one model for a, b, and c, for 
weight and height, respectively). 
In Study II, we selected the time window 0-3 years of age, and included all available 
measurements of growth for each child during this period. In total, 2,874 twins had data 
during this period. As infant growth patterns vary slightly between males and females,
223
 we 
estimated separate average curves for each group. In addition, each of the resulting 
parameters was inspected in terms of the mean and standard deviation for differences 
between these groups. Although this difference was not statistically significant, we still opted 
to standardise the parameters by sex. 
5.3.7 Structural Equation Models – Twin modelling (Study III) 
Structural equation models are often applied in the context of twin modelling. Based on 
correlations of a phenotype within twin pairs for which a certain predetermined genetic 
correlation is assumed (0.5 for DZ and 1.0 for MZ twins), the remaining proportions and 
sources of variation can be calculated.
187
 Heritability is one such factor, usually termed 
‘additive genetics’, or A, in classic structural equation twin models.  
Univariate heritability models focus on one trait or phenotype, and estimate the degree to 
which components A (additive genetics), C (shared environment) or D (genetic dominance), 
and E (non-shared environment) contribute to the total variance of this phenotype within the 
population.
224
 The sum of these contributing factors is always 1, i.e. the whole. Additionally, 
bivariate heritability models can be constructed to look at the shared heritability of two 
different phenotypes.
225
 Within the scope of this thesis, however, all the heritability models 
that were constructed were univariate. 
The assumptions underlying structural equation twin models include: 
1) The equal environments assumption: stating that we assume that MZ and DZ twins share 
their environment to an equal degree within the pairs. 
2) There is no gene-environment interaction 
and  
3) There is no assortative mating 
Of these, the non-assortative mating assumption has been challenged recently. One recent 
study has shown that when it comes to psychiatric diseases, this assumption likely does not 
hold.
226
 However, as we have yet to see such evidence for asthma, in this case we have 
elected to assume that the assumption is mostly correct. 
Finally, twin models are formulated as either ACE, ADE, or AE, depending on the 
correlations within different zygosities (ADE was selected when the tetrachoric correlation in 
MZ pairs was more than twice that of the DZ-ss twins) and if a simpler model would suffice 
(AE was used in place of A(C/D)E if a likelihood ratio test (LRT) comparing the more 
 36 
complex to the simpler model revealed that the extra parameter did not significantly improve 
the model fit). The software used to construct the twin models and perform these calculations 
was OpenMx.
227
 
5.3.7.1 When the importance of genetics varies by sex 
Typically, only same-sexed DZ and MZ pairs are included in twin modelling. This was also 
the case in the main analysis in Study III. The reason for this is a wish to circumvent the risk 
that potential confounding by sex would somehow influence the associations. However, the 
prevalence of asthma is known to differ by sex, with the age group under study here being of 
particular interest (as it is just before the ‘puberty switch’ – at which the prevalence of asthma 
changes from being higher in males to instead being higher in females
228
).   
In addition to the basic features of univariate twin models, opposite-sexed DZ twin pairs can 
provide extra information which cannot be attained from using only the same-sexed DZ pairs. 
In this case, sex limitation models can be specified.
229,230
 These constitute varieties of 
structural equation models that allow for either 
1) A factor rA which is a multiplier of sex (qualitative difference – this allows for different 
genes to be of importance for different sexes) 
or 
2)   making separate estimates of each variance component by sex (quantitative difference – 
this implies we believe they are the same genes, but their importance differs).  
To determine which of these – if any – was the case, the models were fitted in different 
combinations to the data, after which the fit of these models were compared via another LRT. 
5.3.8 Differential methylation and limma models 
Prior to the differential methylation analyses in Study IV, CpG probes were filtered based on 
intensity, proximity to a SNP, and location on sex chromosomes. The final number of CpGs 
retained after this process had been completed was 485,117 (94% of the original ~485,000).  
After CpG cleaning and data normalisation using the dasen method,
231
 we analysed the DNA 
methylation data using Linear Models for Microarray Data (limma),
232
 as incorporated within 
the R package RnBeads.
233
 Briefly, limma models are linear models specifically designed to 
handle data from microarrays such as the Illumina 450k Beadchip. The measure of DNA 
methylation at each CpG site going into this model is the M-value: the log2 ratio of 
methylated vs. unmethylated probes at each site. A related estimate, the beta value, is defined 
as the ratio of the intensity of the methylated to the sum of the unmethylated and the 
methylated probes.
234
  
Differences in M value between cases and controls were calculated to identify CpG sites with 
significant differences in methylation. For these, absolute values of the average methylation 
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in each group were also presented. P-values obtained using this method were presented both 
in unadjusted and false-discovery-rate-adjusted (FDR-adjusted) form.  
5.3.8.1 Confounding by cell type 
We aimed to correct for the composition of each study participant’s WBC by adjusting the 
limma models for one of two ratios: the neutrophils to leukocyte ratio (NR) or the eosinophil 
to leukocyte ratio (ER). When included as in the models, the ratios were treated as continuous 
variables. In the manuscript, we referred to this adjustment as correcting for confounding by 
cell type. However, it should be noted that we adjusted for each of these cell type ratios 
independently. This was done because they are correlated to each other, but also because they 
might capture slightly different things. 
5.3.8.2 Confounding by genetics 
The main method of adjusting limma models for confounding by genetics was by performing 
analyses within asthma-discordant twin pairs. For further explanation of the rationale behind 
this method, see below. 
5.3.9 Within-pair and co-twin control analyses 
 
Within-pair and co-twin control analyses are essentially part of the same concept, but the 
terms are used to imply slightly different applications of the underlying principle.  
Briefly, the point of both analysis methods is to identify the twin pairs who are discordant for 
both the exposure and the outcome, and then to study the exposure–outcome association 
specifically within these pairs. This ‘model’, if one would like to refer to it as such, is then 
naturally controlled for all factors that are shared within the twin pair. For instance, the twins 
will have both been exposed to potential maternal smoking during pregnancy – this shared 
environmental factor can no longer confound any association remaining within the pair. In 
the case of MZ twins, the shared factors include their entire set of potentially segregating 
genes; which are only shared to on average 50% between DZ twin pairs.
235
 
Within-pair analysis, for instance within asthma-discordant monozygotic twin pairs (Study 
IV), is thus a very elegant model allowing for interesting conclusions regarding what may still 
remain to have made these twins different in terms of disease.
214
 These within-pair 
comparisons are often carried out in parallel within several discordant pairs of the same 
cohort, to attempt to identify differences that are shared between several twin pairs. 
Co-twin control analysis, as the term is most commonly used, involves making these within-
pair analyses both within MZ and DZ twin pairs. The strength of any potential remaining 
association is compared between the zygosity groups. As comparisons within MZ twin pairs 
allow for additional controlling for shared genetic factors, an association that was visible in 
DZ but disappears in MZ twin pairs may have been partially explained by the genetic 
variation that has now been completely controlled for. Because this method assumes that the 
underlying zygosity assessment is reliable, twin pairs with unknown zygosity should not be 
included.  
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6. ETHICAL CONSIDERATIONS 
6.1 RISKS FOR THE STUDY PARTICIPANTS 
Medical research involving human subjects carries with it special challenges and 
considerations no matter the topic of said research. The potential benefit of the research 
always needs to be balanced against the risk to which the study participants are subjected. 
Withdrawal of blood and other biological samples causes discomfort and may be an 
unpleasant experience for some study participants. Efforts to minimise this discomfort 
included providing the study participants with information beforehand, as well as providing 
patches with local anaesthesia cream for application prior to the clinical examination in 
STOPPA (Study IV).  
As this clinical examination included some blood and lung function tests which could reveal 
current health issues, the results of these tests were reviewed by a specialist in paediatric 
medicine. Twins whose white blood cell counts lay outside of the normal range or whose 
spirometry results suggested underlying pathology were contacted following the clinical 
examination and encouraged to get in touch with their general practitioner.  
6.2 INFORMED CONSENT 
It is also important to remember that informed consent is a cornerstone of all medical 
research. The right to have research to which one is asked to participate explained in 
understandable terms, as well as the right to decline participation in said research, is governed 
by international directives
236
 as well as Swedish law.
237
 In Sweden, particular care is also 
taken to emphasise the considerations needed to be taken for medical research concerning 
minors. 
In all of the studies included in this thesis, the study participants were younger than 18 years 
at the time of participation in the research. The approaches taken to consider this were 
slightly different between studies because the age of the study participants varied. One 
recommendation based in Swedish law states that an individual who is between 15 and 18 
years of age should be allowed to make their own decision regarding their participation, 
provided that they can be expected to understand what the study entails on their behalf. 
Therefore, in Study II, twins’ own consent was requested for growth data collection, whereas 
in Study IV, consent was collected from both twins and parents. 
6.3 PRIVACY AND INTEGRITY 
On the other hand, due to the extensive nature of the information collected in epidemiology, 
particularly in register-based and genetic studies, a larger concern is that of potential 
violations of integrity. Great care is taken to protect the privacy of study participants. In all 
research and analysis data sets, names, personal identification numbers and other pieces of 
information that can be used to identify a study participant have been removed, replaced with 
an anonymised study participant number. 
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6.4 DATA SECURITY 
While handling  detailed data including information on genetic and epigenetic variation, data 
security is of particular importance. Therefore, in addition to ensuring the integrity of 
individual study participants by anonymising the data, the data themselves are protected by 
storage on secure servers. For each project included in this thesis, data has been stored in the 
most restrictive way possible, granting access only to those individuals who are involved in 
the project in question. 
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There is nothing like looking, if you want to find something. You certainly usually find 
something, if you look, but it is not always quite the something you were after. — J.R.R. 
Tolkien, The Hobbit 
7. MAIN RESULTS AND DISCUSSION 
7.1 TWINS AND THE OUTCOME – DIVING DEEPER INTO STUDY I 
 
Study I took place within population-based registers. The total number of study participants in 
the two cohorts was 1,247,952 – children born in Sweden over the course of 13.5 years. 
These were divided into two different cohorts: the older cohort (born 1993-2001) and the 
younger cohort (born 2005-2009).
238
 We found slightly different results in each of these 
cohorts. Briefly, there was an increased risk of asthma for twins compared to singletons in 
crude analyses in the younger cohort – but not in the older. Adjusted models (covariates were 
gestational age, birth weight, Apgar score, mode of delivery, presence of older siblings, and 
parental education) showed lower risk of asthma in twins in both age groups. 
Some studies of asthma in twins (or other multiple births) versus singletons were published 
before ours.
64,65,68,239-243
 Together, these spanned a variety of ages, starting from birth 
65,68,240
 
and going well into adulthood.
239,242
 Figure 9 shows available effect estimates (OR, HR, or 
RR) from these studies as well as our own.  
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Figure 9 Findings from available studies of twinship and asthma reporting effect estimates as either 
Odds Ratios (OR), Hazard Ratios (HR), or Relative Risks (RR). Estimates are presented roughly 
according to the age range of the participants (from youngest to oldest) and whether the estimate is 
crude or adjusted. YC = Younger cohort of Study I. OC = Older cohort of Study I. 
As seen here, there is no clearly discernible pattern within this collection of results. 
Additionally, the many facets of heterogeneity between the studies (including different 
statistical models) likely preclude direct comparisons of the estimates. Still, it is worth noting 
that the younger cohort (YC) in Study I  is the only one in which there was a statistically 
significant higher risk of asthma in twins in crude analyses. 
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7.1.1 A true difference by age – or something else? 
As our intention in defining the cohorts in this way was to be able to discern differences 
related to age, as well as to use different statistical models and effect measures, it is tempting 
to allow the explanation to remain centred on these factors. But what if it is something else?  
Children age, yes – but the times change, too. One thing that has changed over the years is the 
proportion of children delivered by caesarean section. 
Figure 10 (below) shows the proportions delivered by caesarean section (elective or 
emergency) in the twin vs. singleton group. The x axis displays the birth years (note the slight 
jump between 2001 and 2005: this was the gap between the two cohorts). 
 
Figure 10 Proportion of deliveries (%,on the y axis) by caesarean section in Sweden during the time 
period (calendar years, on the x axis) when the participants in Study I were born.  
By 2009, more than half of all twins were delivered by caesarean section (CS), compared to 
just over a third in 1993. However, the relative increase in this proportion within the singleton 
group during the same time period was actually larger (from 10 to 17%, a 71% increase). 
These figures reflect changed practices within this time period – particularly between 1993 
and 2001. 
While changed practices aiming toward the earlier delivery of twins could be expected to lead 
to an increase in elective CS in the twin group as a whole (which it did, by 29%), but there 
was also an increase in emergency (i.e. non-planned) CS during the time period. Indeed, this 
increase was larger: from 17 to 30%, a 76% increase. This change is shown over time in 
Figure 11 (again, note the skip on the x axis due to the time gap between the cohorts). 
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Figure 11 Proportion of twin deliveries (%, on the y axis) by emergency or elective caesarean section 
in the Study I population – calendar years 1993 to 2009 (x axis). After each starting out at 17% of 
twin deliveries in 1993, proportions of both emergency and elective caesarean section increased by 
2009. 
Among singletons, there was a 60% increase in elective CS but an 85% increase in the 
proportion of emergency CS. Another potential driving factor behind an increased proportion 
of elective caesarean sections is the woman’s own decision; however, this only concerns 
about 8% of CS in Sweden, according to a recent report published by the National Board of 
Health and Welfare.
209
 The mother’s preference could be expected to lead to an increase in 
elective CS, but as can be seen here, it did not explain the increase in CS deliveries overall.  
But how might these changes have affected our associations? Well, for one thing, CS in itself 
has been found to be associated with increased risk of asthma in some studies
244-248
 – but it 
has also been shown that this is primarily true for the emergency CS, perhaps as a 
consequence of stressors in the foetal environment.
208
 If that is the case, the increasing 
proportion of emergency CS within the twin group in the time span covered by the younger 
cohort could have contributed to the initially higher risk of asthma in twins vs. singletons in 
the younger age group vs. in the older (where the crude effect was not significant). It could 
also explain why adjusting for this factor seemed to have different effect sizes in the different 
age groups. 
We adjusted for mode of delivery in some of the adjusted models. For example, see model 3 
and the fully adjusted model, Table 3 (older cohort) and Table 4 (younger cohort) in the Study 
I publication.
238
 In summary, model 3 included mode of delivery, Apgar score, parental 
education, and presence of older siblings. The fully adjusted model included all of the above, 
but also gestational age and birth weight. Not only are gestational age and birth weight 
closely related, but each of these are also associated specifically with mode of delivery, 
because intrauterine growth restriction is a common reason to deliver a child by elective or 
emergency CS, and this also leads to a shift towards lower gestational age. 
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And let us discuss the issues of gestational age and birth weight further. Was the 
distribution of these important covariates different between the older and the younger cohort 
– perhaps as a consequences of changed practices in deliveries? Figure 12, below, shows the 
distribution of gestational age in twins in the older versus the younger cohort. 
 
Figure 12 Proportion of births (%, on the y axis) by gestational week in twins of the  younger vs. 
older cohort of Study I 
There appears to be a slight shift of the orange (younger cohort) curve towards earlier 
gestational ages - at least in the lower and higher ranges. But, as can be seen, the absolute 
differences were very small; it wasn’t a dramatic shift. A two-sided t-test (with unequal 
variance) of these groups versus one another revealed a significant difference of the mean 
gestational age between the younger and older cohort group (37.3 weeks in the older cohort 
vs. 36.9 weeks in the younger, corresponding to an absolute difference of about three days). It 
is however unlikely that the impact of this small difference would be large enough to make a 
significant contribution to the differences in the crude associations between twinship and 
asthma in the younger vs. older cohort. 
An additional factor which has changed over time is the structure of registers. Before 2001, 
diagnoses from outpatient specialist clinics were not reported to the NPR. This means that the 
outpatient diagnoses of the full younger cohort were covered from birth – but the oldest 
participants in the older cohort did not have their outpatient diagnoses registered in the NPR 
until from 8 years of age.  
Thus, there have been some changes over time in terms of mode of delivery, gestational age, 
birth weight, and methods of recording asthma diagnoses. All of these could have contributed 
to the different patterns of association of twinship and asthma between age groups. The use of 
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population-based registers also meant that information on many environmental factors – 
which may also have varied over time – was not available, although these could also explain 
some of the difference. Moreover, the de facto age difference can in itself still be an 
explanation. In the event of a future iteration of this study, individuals born over a longer time 
period and with improved register coverage could be included – this would probably reduce 
the influence of most of the variations discussed here. 
7.1.2 Is there any support for the ‘healthy twin’ effect? 
One potential explanation for the decreased risk of asthma in twins after adjusting for 
gestational age and birth weight is the so-called healthy twin effect.
249
 The principle behind 
this is that if twins are more likely to be under physiological duress during pregnancy than 
singletons, they may thus require greater physical fitness merely to cope with the demands in 
utero. Adjusting for birth weight (or gestational age
250
) could make the healthy twin effect 
even more visible, and introduce a birth weight paradox.
251
 This implies that adjusting for 
birth weight accounts for one of the primary ‘unhealthy’ mediating pathways between the 
exposure (in this case twinship) and the outcome – and that the remaining effect can to some 
degree be attributed to biological selection (i.e. survival despite challenges in utero). 
This would suggest that twins are more fit for early delivery, owing to some special quality of 
twin pregnancies,
252
 and perhaps explained by a physical need to be delivered earlier due to 
lack of space in utero. If that is the case, an interesting alternative would be to stratify twins 
and singletons not by their gestational age or size at birth, but by their health status. 
Outcomes chosen from the neonatal period have so far been the closest approach to this. 
Studies have compared twins and singletons matched for growth restriction
253,254
 or 
gestational age,
255-257
 but these matched studies did not find any significant differences in 
neonatal outcomes, including mortality, intraventricular haemorrhage, pneumothorax and 
early sepsis – which would have been expected in the presence of a healthy twin effect or 
paradox. Twins did seem to be protected to some degree from consequences of maternal 
pregnancy complications (gestational hypertension
258
 and diabetes
259
), which could indicate 
something particular about twin pregnancies as such. A recent meta-analysis indicated that 
short time outcomes, specifically stillbirth and neonatal mortality, differ by chorionicity in 
twin pregnancies
260
 – if possible, future studies comparing twins and singletons should take 
chorionicity into account. 
It may be the case that twins or twin pregnancies are adapted to combat some challenges 
early in life, but it remains largely unclear what happens to those health adaptations over 
time. One Swedish study of twins born from 1932-1958 did not reveal any differences in 
terms of the risks of cancer, cardiovascular disease or all-cause-mortality in adult twins vs. 
singletons.
261
 These twins and singletons were not matched for birth weight or gestational 
age, although low birth weight is known to increase the risk of cardiovascular disease in 
singleton children.
57
 The apparent lack of long-term effects might indicate that differences 
arising from twins’ and singletons’ different physiological adaptations to the intrauterine 
environment lose relevance over time.  Whether the effect is similar in terms of other 
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childhood (or indeed, adult) outcomes than asthma, however, remains to be assessed. Such 
analyses could be relevant for researchers studying other outcomes in twins.  
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7.2 EARLY GROWTH – SOMETHING DIFFERENT IN TWINS? STUDY II 
In Study II (included in manuscript form), we modelled SITAR parameters a (size), b (tempo) 
and c (velocity) against asthma during childhood and adolescence.  We were not able to 
identify any significant effects of early growth beyond a slight delay (both in terms of weight, 
Table 2, and height, Table 3 in the manuscript) in twins with asthma. After adjusting for 
factors related to foetal growth, this effect was no longer significant. 
7.2.1 Closing a door and opening a window – aiming for the right time 
period in terms of exposure and outcome 
We chose to model growth between 0-3 years of age for two reasons. By starting shortly after 
birth, we capture one of the earliest and most rapid phases of human growth. It is also within 
segments of this time window that previous studies have observed associations between early 
growth and asthma. Figure 13 shows the time windows within which previous studies
95,98-110
 
have found associations with rapid or increased growth and asthma or wheeze. 
 
Figure 13 Time windows (months to years of age) covered by previous studies finding associations 
between early childhood growth and wheeze or asthma. 
Notably, many of these studies – particularly those on wheeze100,102,105,110 – saw their main 
findings between 0-3 or 0-6 months. It is possible that selecting the relatively wide age span 
0-3 years for Study II caused us to miss some true differences that may have been present 
early on, but evened out over the course of the follow-up. It may also be of importance to 
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consider the coverage of growth data in relation to the time point(s) at which the asthma 
outcomes are defined. In a previous study that included asthma at several different ages (8, 
14, and 17 years
109
) as outcomes, rapid weight gain during three different time intervals (0-3 
months, 3-12 months, and 1-3 years) before 3 years of age were positively associated with 
current asthma at 8 years of age, but not at 14 years. This could imply either that early growth 
is less important for asthma that occurs later in childhood, or that it is the time that has passed 
since the rapid growth occurred in itself that makes a difference regardless of when the rapid 
growth took place. In Study II, we defined asthma as ever-asthma (occurring by 15 years of 
age – sometimes up to 18 years depending on the NPR and SPDR coverage) or asthma after 3 
years of age, both of which will have combined early and later childhood asthma as one 
phenotype. Because the wheeze phenotype in CATSS only includes the children with wheeze 
who do not have asthma, we did not include this phenotype in Study II. This may have 
complicated comparisons to previous studies in which the  asthma outcome included 
wheeze,
99,101,103
 if it was the latter aspect of this phenotype that drove the original association. 
7.2.2 Particulars of growth in twins – possible biological and behavioural 
origins 
Another plausible explanation for our failure to find associations similar to those in previous 
studies would be that there is something particular about the way twins grow.  
Let us consider the possibility that childhood growth – after birth – is recalibrated to start 
acting as postnatal growth regardless of which gestational week the child was born in. 
Specific growth charts have been constructed for the purpose of comparing the postnatal 
growth of prematurely born children to the interrupted foetal growth.
262
 But our data did not 
take the twins’ gestational age into account; one possibility would have been to offset the age 
recorded in the model by the number of weeks the birth was premature. On the other hand, if 
twins ‘adapt’ at birth to postnatal growth regardless of which gestational week they were born 
in (or indeed, if twin pregnancies are somehow biologically calibrated to be different and end 
sooner – as was discussed in connection with Study I), then such an approach would have 
been erroneous. 
One potentially important factor on which we lacked information within the CATSS 
population was breastfeeding. Infants who are breastfed have slightly different early weight 
gain compared to formula-fed infants. Breastfed babies usually lose slightly more weight 
immediately after birth, and show a slightly less pronounced weight increase over the first 
months.
263
 
It is possible that twins are breastfed less than singleton children.
264
 This could in turn mean 
that fewer children in our study population have been breastfed than if we had conducted the 
same study in a singleton population. On the other hand, the prevalence of breastfeeding 
varies between countries,
265
 and it’s difficult to say what impact this would have had on the 
possibility of comparing our results and those of other studies. 
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7.2.3 Does birth weight discordance preclude co-twin analysis in terms of 
growth? 
It is common for twins to display some degree of within-pair discordance in birth weight.
75
 
Potential reasons for this include differences in placentation, chorionicity and the competition 
for nutrition and space in utero.
182
 If these factors differ between MZ and DZ pairs – and they 
do, because monochorionicity is more common in MZ twins
266
 – the equal environments 
assumption may be threatened – albeit in an unconventional way. Concerns regarding the 
validity of this assumption usually involve excess environmental similarity between MZ as 
compared to DZ twins. In the case of monochorionicity and potential uneven distribution of 
nutrients within the twin pair during pregnancy, the opposite might be true. Selecting twin 
pairs discordant for birth weight would then result in a subgroup in which these differences 
are enhanced. 
A difference in the frequency of occurrence of a phenomenon on its own, however, does not 
automatically translate to its biological importance. The subject also gives rise to the question 
of when, exactly, we should consider that differences in environment by zygosity are a 
potential concern. Assuming for a moment that the effects of chorionicity and placentation 
are strong enough to constitute a significant environmental factor with long-term 
consequences, it could be of importance also for studies of other exposures – not just those 
occurring closely to the prenatal period. Based on available knowledge of the biological 
impact of differences in chorionicity – the implications of which are incompletely known, 
especially in comparison to the many of environmental factors that twins of all zygosities 
share
187
 – it is not possible to give an exact estimate of the impact of this potential problem on 
any outcome.  
In summary, the assumption of equal environments within twin pregnancies of different 
zygosity may be a concern, but it is far from clear how great a concern it is, and this 
limitation is not necessarily greater in studies of growth than of other outcomes that may in 
some way be associated with the intrauterine environment. 
7.2.4 Limitations of using registers as a data source for birth weight in terms 
of twins 
During the 1990s, when the participants of Study II were born, children were not assigned 
their PIN until a few days after delivery. Medical Birth Register information was not formally 
assigned to each child until the PIN had been established. For singleton children, this would 
have presented no problem. But among twins, it could lead to mix-ups of birth weight within 
the twin pairs. 
We were able to deal with this problem to some extent in Study II by comparing parent-
reported birth weights with those recorded in the register. This was not possible in Study I, 
which did not use CATSS data. The method used to correct for this primarily relied on 
agreement between the parental and register-based reports, in which case the register-based 
value was used. An alternative might have been to rely solely on the parents – 
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 but the potential consequences of this option have not been thoroughly investigated.  
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7.3 GENETICS VS. EPIGENETICS – STUDY III AND IV 
Study III and Study IV both probe the balance between genes and environment. Study III 
primarily displays the relative contrast between the two, whereas Study IV illustrates a 
phenomenon that has long been thought to constitute a bridge between them. 
In Study III, 
267
 twin models showed that additive genetics (heritability) was consistently the 
most important factor behind the variability of all asthma and related allergic phenotypes 
(Study III, Table 2). This isn’t to say that the shared- and non-shared environment were of no 
importance. They were quite influential, too, but twin models do not allow us to identify 
which specific environmental factors were at work. 
Although the same is true for the genetic component from a twin model, we also measured 16 
selected SNPs. Of these we were able to replicate associations for six: rs3771180,  
rs2305480, and rs11078927 – where the minor alleles were protective – and rs12936231, 
rs7216389, and rs3894194 – where the minor alleles were associated with an increased risk 
of asthma. Altogether, these contributed a fraction of a percent of the estimated heritability in 
the full sample. Thus, while the individual effects of the SNPs were statistically significant, 
the total impact of these genetic variants was very small. While this is to be expected based 
on a selection of variants that was restrictive to begin with, increased knowledge regarding 
which specific genetic variants replicate between populations and phenotypes can still be 
highly beneficial – particularly in terms of extending these findings into investigations of 
downstream effects or potential therapeutic implications. 
On that note, it is of particular interest that many of the replicated SNPs were found within 
the ORMDL3/GSDMB region, as our understanding of the function of these genes has 
increased in recent years.
268
 The field still has some way to go before this knowledge can be 
translated to clinical practice – something that will likely require integration with subsequent 
studies including gene expression and epigenetic changes. 
It’s sometimes said that epigenetics may be one of the explanations behind the so-called 
missing heritability, but this is not entirely true. Largely, this statement probably arises from 
a misunderstanding of the concept of heritability. In reality, epigenetics may be part of the 
heritability (in the sense that it is not independent of genetic variance
126
), but should be seen 
as primarily a mediating mechanism for actions of the shared- and non-shared 
environment.  
So what evidence did we find for such mediation in Study IV? At first glance, crude analyses 
revealed 340 CpG loci with statistically significant associations with childhood asthma – but 
the absolute differences in methylation between twins with and without asthma were only a 
few percent for each locus. Additionally, these CpGs represented several genes, but only six 
of these (ACOT7, IL13, KIAA0182, MAD1L1, SLC44A4 and ZFPM1
171
) replicated results 
from previous studies, which, moreover, have only rarely agreed with each other before. 
There may be several reasons for this persistent difficulty in obtaining consistent findings, 
one of which was elegantly illustrated in our results by the fact that adjusting for cell count 
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ratios weakened all of the previously found associations to the point that they were no longer 
significant at the false discovery rate-adjusted level. Cell counts in whole blood have to our 
knowledge only been accounted for in this manner in one previous study on DNA 
methylation in asthma.
269
 
One reason for our failure to identify CpG loci that were stable following adjustment for 
genetic confounding is the limited number of asthma-discordant pairs and consequently lower 
power in the within-pair analyses. However, asthma-discordant MZ pairs are rare, and 
became rarer still between recruitment from CATSS and the clinical examinations in 
STOPPA. When co-twins who had previously been considered healthy controls were 
redefined as cases, previously asthma-discordant pairs became asthma-concordant.   
An interesting feature of comparisons of the findings from Study III and Study IV was the 
lack of overlap between genetic regions of the significantly associated SNPs and CpGs. 
Although the SNPs in Study III were a highly selected group, the fact that they were hand-
picked based on previous associations makes them more interesting. However, although some 
of the CpG sites that ranked highest in the crude model were also located on Chromosome 17  
(Study IV, Table 1 – specifically cg05613273, cg14611258, and cg13054523), these were not 
located anywhere near the ORMDL3/GSDMB region. This may imply that any interaction 
between genetic and epigenetic variation that is relevant to this phenotype occurs between 
different genomic regions. Studies including both GWAS and EWAS data from the same 
individuals may be able to identify these interactions in the future. 
7.3.1 If not epigenetics, then what? 
There has to be some kind of biological difference between the twins within disease-
discordant pairs - after all, if there wasn’t, one twin would not be sick while the other is 
healthy. And yet, after correcting for genetic and cell-specific effects, we found little on the 
epigenetic level. 
Potential explanations include that the differences are instead found in terms of gene 
expression, protein synthesis, metabolites, or other biomarkers.
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 All of these explanations 
involve biological mechanisms occurring ‘one step down’ from the genetic and epigenetic 
level. In that sense, these biomarkers are also excellent choices for validation studies of 
epigenetic findings. Until we have consistent, strong, replicated findings on the epigenetic 
level, expression and other downstream studies may have to take up the hunt on their own. 
That said, there are other methods of measuring epigenetic differences – including histone 
acetylation
271
  – and it may be that the differences that are most relevant to asthma are on this 
level, or that they are not covered by currently available arrays. 
Finally, gene-environment interactions
272,273
 and epigenetic cross-talk 
274
 may also be relevant 
in this context.    
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8. OVERARCHING METHODOLOGICAL 
CONSIDERATIONS 
It just as important to be aware of the limitations of scientific work as it is to know its 
strengths, if not more so – for it is only by acknowledging the weaknesses in our work that 
we can improve upon them. 
8.1 SELECTION BIAS, CONFOUNDING AND THE REMAINING MERIT OF 
OBSERVATIONAL STUDIES 
The population recruited for Study II was selected via the child growth data collection, which 
led to an unexpected under-representation of boys.
199
 Given that recruitment to all of the 
CATSS cohorts has involved some degree of non-response,
196
 it is likely that additional 
factors have been unequally distributed between responders and non-responders. Although 
this has not been investigated in detail, the mere likelihood of unequal distribution does not 
automatically imply that there is selection bias, as bias requires these additional factors to be 
associated with both the exposure and outcome of the new study.
14
 
Observational studies share an inherent weakness: we can never be completely sure whether 
or not an observed association might have arisen through uncontrolled, unmeasured, or 
residual confounding. With the help of DAGs
216
 and access to data on many of the important 
covariates of interest, we have tried to account for as much confounding as possible within 
these studies. Still, some potential sources of confounding remain. For example, birth weight 
is only a proxy of prenatal growth and residual confounding may remain even after 
adjustment (Study I and II). Further, there were no data on breastfeeding, making this an 
uncontrolled potential mediator between infant growth and childhood asthma (Study II). 
Finally, adjusting for proportions of white blood cell populations may have obscured true 
differences occurring primarily within these cell types that were still disease specific (Study 
IV).  
Although randomised intervention studies are designed to circumvent most of the 
aforementioned issues, this study design would not have been an option for the exposures 
studied within this thesis. Neither twinship (Study I), early childhood growth (Study II), 
genetic variants (Study III), nor DNA methylation (Study IV) can be randomised. 
8.2 MULTIPLE TESTING, FALSE POSITIVES AND HOW THESE MAY EXPLAIN 
FAILED REPLICATION EFFORTS 
In any study where a large number of statistical tests are run in parallel, it is possible for false 
positives to arise purely by chance – these are then referred to as type I errors.275 It is the 
researchers who decide which statistical significance level to employ, and thereby how often 
we accept that this might happen. An option for dealing with this is to correct the estimates 
for the number of tests performed, such as by Bonferroni correction (Study III) or utilisation 
of false discovery rate-adjusted p-values (Study IV).  
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Even so, it’s still possible for false positives to slip through the net. Particularly in a study 
based on array data (such as Study IV), we cannot exclude that some type I errors will remain 
even after correction. False positive findings in the studies from which we selected the 
genetic variants to feature in Study III could be a potential explanation for why we were not 
able to replicate associations for all the selected SNPs in our cohort. 
8.3 MISCLASSIFICATION AND LACK OF SPECIFICITY OF THE OUTCOME 
As was introduced previously, asthma is likely not a single disease – not even in childhood. 
But throughout this thesis, it has largely been treated as one. Retrospectively asking about 
‘asthma ever’, which was a variable that went into construction of the outcomes in both Study 
II and Study III, will inevitably lead to a muddling together of all of these potentially different 
phenotypes. On the other hand, in Study III, we used a set of different definitions of asthma 
(including by diagnosis, medication, or questionnaire), and results were similar between these 
definitions. 
Another inherent limitation in all of our asthma definitions is that we did not take any 
information about triggers for the asthma attacks into account. It is possible that asthma that 
is primarily allergic in nature has different risk factors and genetic components that are 
relevant.
276
  
Still, some of the definitions are probably better than others. The medication and diagnosis 
outcomes used in Study I and Study III were validated against clinical records, but the self-
reported asthma in CATSS-9/12, CATSS-15 / CATSS-15/DOGSS, and STOPPA has not yet 
been validated, although the questionnaire design is based on the International Study of 
Asthma and Allergies in Childhood (ISAAC) questionnaires,
277
 which were. 
Additionally, data collections in Study II and Study IV contained questionnaire responses 
from both parents and twins. In Study IV, we only used the parent-report of current asthma, 
but for Study II we used any report of asthma at any time up to 15 years of age, regardless of 
whether it had been reported by the twin or the parent. This was done because not all parents 
of twins at age 15 had responded, and using parent data exclusively would have meant 
missing data unnecessarily. Exclusively using twin data, on the other hand, might have 
caused us to miss out on diagnoses the twins did not themselves remember having received. 
Including any reported asthma, even if the parents and twin had all responded and disagreed, 
means we may have introduced some misclassification. 
As diagnoses in primary care are not covered in the NPR, it may be argued that the patient 
population featured in the national patient register (first the inpatient register, and later also 
the outpatient register) is enriched to contain the more severe cases. This is probably true, but 
also including the medication outcomes from SPDR – which may have been prescribed 
anywhere – should circumvent the problem.207 
Some studies argue that severe asthma constitutes its own phenotype.
278
 In that case, results 
from our studies using patient register-based outcomes may be less generalisable to the 
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population of children with asthma as a whole. However, as the subgroup of children with 
very severe asthma is very small, any particular characteristics of this group should have had 
only minor effects on the overall results.
279
 
Finally, one of the studies within this thesis (Study III) also examines other phenotypes 
besides asthma (hay fever, atopic eczema, and food allergy). All of these definitions were 
purely questionnaire-based and from parental report, which is a limitation. An alternative 
would have been to use medication proxies also for these outcomes – but an attempt to 
identify similar outcomes for eczema as for asthma
207
 was not as successful. This may be 
partially attributed to the less specific prescription patterns for these diseases (especially for 
atopic eczema), but also to the fact that many of the medications used for allergic diseases in 
Sweden are sold over the counter (i.e. without the need for a prescription), and thus not 
captured in the SPDR. 
8.4 MISCLASSIFICATION OF EXPOSURE 
8.4.1 Measuring the right thing – in the right twin 
During the clinical examinations in STOPPA (Study IV), the identity of each twin within the 
pair was confirmed at every step of the examination when data was recorded, and samples 
and tubes were clearly labelled to avoid mix-ups within the twin pair to the greatest degree 
possible. Since we did not have the same strict oversight over collection of the first-hand 
growth data measurements in Study II – and the twins were often measured at the same age, 
presumably at the same visit – here we have to rely on the accuracy of the original records. 
For Study III, it was the twins themselves who collected the saliva samples and mailed them 
to the KI Biobank, where they were stored until the genetic analysis could be undertaken. 
Although mistakes may have occurred at any stage during any of these collection processes, 
most likely the human error was rare and the control mechanisms in place (labels and identity 
checks) will have sufficed to reduce this risk to its smallest potential. In the cases where any 
mix-ups remain, they should be of a random (i.e. non-systematic) nature, and hopefully rare 
enough that their effect would be small. 
8.4.2 Biological targets – testing the right tissue 
Study III and Study IV both include analyses of biological materials: saliva (for DNA, in 
Study III) and whole blood samples (for DNA methylation, in Study IV). The intention in this 
case is to acquire a sample that is representative of the individual and, potentially, the target 
tissue of the disease. 
For DNA, the process is made simpler by the fact that all nucleus-bearing cells in an 
individual’s body share the same genetic code (in principle, at least – although over time 
mutations both with and without consequences may occur in individual cells). Therefore, 
epithelial buccal cells (such as those that can be found in a saliva sample) contain the same 
DNA as a cell from the blood of the same individual. That isn’t to say that a saliva sample 
cannot also contain DNA from other organisms – indeed, it is largely for this reason that 
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DNA extraction kits are specific to human or, for instance, bacterial DNA.
280
 It is also 
possible for DNA samples to be contaminated by other human DNA during the collection or 
handling process – although great care is taken to avoid this in laboratory settings. 
With DNA methylation, on the other hand, the cell type matters.
127
 This was why we chose 
to measure white blood cell counts as well as DNA methylation. Another way of handling 
potential variations in cell type composition is to only analyse a selected target tissue – a 
strategy often applied in studies of DNA methylation in asthma.
171,172,177,281,282
 In many ways, 
this makes sense – but choosing a specific tissue type comes with its own assumptions. The 
researcher needs to be fairly sure that the selected tissue or cell type has clear implications in 
the disease under study, or else run the risk of performing the time-consuming (not to 
mention still rather expensive) analysis only to wonder if the actual epicentre is somewhere 
else.  
Whole blood has commonly been analysed in DNA methylation studies, and therein lies a 
clear advantage to using blood samples: because they are easily accessible (especially 
compared to tissue biopsies), they have been used to study many different outcomes. This 
allows for more straightforward comparisons of results between studies, as well as for 
collaborations. In the long term, methylation patterns detectable in whole blood may also be 
of interest in clinical settings. 
8.4.3 Twin pair similarity – strength or weakness? 
Without the assumption that twin pairs share a large fraction of their genes and environment, 
twin modelling and co-twin control analyses would not be possible.  
But some might argue that the fact that a twin is part of a pair might threaten the validity of 
reporting of outcomes and exposures within this pair. Parents of twins could be thought to 
over- or understate the similarity within the pairs – and the twins themselves could, too. 
Technically, this would constitute a form of sibling imitation or contrast effect – a 
phenomenon that has been described in twin studies of attention-deficit hyperactivity 
disorder.
283
 If similarity within twin pairs is exaggerated, this could lead to a perceived high 
prevalence of the outcome in a twin population as compared to a roughly equivalent singleton 
population. On the other hand, if there is a counter-acting tendency to also overstate 
similarities in terms of not having the outcome, these two sides of the same mechanism may 
balance each other out. 
We did observe relatively high prevalences of any asthma in Study II and Study III, however. 
Then again, these were cumulative outcomes – and prevalences from studies using similar 
reporting methods in Swedish singletons are also high.
24
 The prevalences of our asthma 
outcomes in the register-based twin studies (Study I and Study III) were not so high as to 
make us suspect that sibling imitation or contrast effects would be a concern within health-
care contexts.  
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Still, if sibling imitation or contrast effects occur it would lead to misclassification of either 
exposure or outcome. In terms of the heritability analyses in Study III, exaggerating 
similarities within the twin pairs could lead to generally higher within-pair correlations and 
thus an underestimate of the importance of the unique environment – the opposite would be 
the case if the bias were reversed (i.e. by overstating differences within the pair). In Study II 
and Study IV, harmonising the outcomes within the twin pair could have shifted the 
associations towards the null.  
The discussion above is largely centred around sibling imitation or contrast effects as they 
would be associated with potential misclassification of the outcome. Fortunately, most of the 
exposures under study within this thesis were not parent-reported but rather extracted from 
registers (Study I), child health records. (Study II) or biological samples, (Study IV) and these 
sources should not be affected by this mechanism. 
8.4.3.1 Is discordance despite a heavy load of reasons for concordance an indication of a 
different underlying biological mechanism? 
Even in the complete absence of reporting bias in either direction, specifically selecting the 
pairs that are discordant in terms of exposure and outcome may be an issue in terms of 
generalisability. After all, there are so many reasons for twins to be similar. Yet, these 
particular pairs are not – at least not in terms of the outcome under study. Whatever the 
reason for this discordance, we cannot know for sure that the factors setting these twins apart 
are the same as those explaining variation in the population as a whole.  
On the other hand, if the mechanism is not completely different – but instead a super-charged 
version of what occurs in the general population – discordant twin pairs could be seen as an 
ideal setting. Sometimes, representing the full source population is less important than 
finding the most illustrative example of a phenomenon of interest.
15
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9. CONCLUSIONS AND INTERPRETATION 
The true impact of one’s scientific work often cannot be assessed immediately after its 
conclusion, but should be viewed in the context of the on-going development within the field. 
In this time of specialised methodology and highly focused questions, each new finding 
brings its own, if small, piece to the puzzle. In the work described in this thesis, we focused 
on transmitted (additive genetic factors and single-nucleotide polymorphisms, Study III) and 
acquired (early childhood growth parameters, Study II, and DNA methylation, Study IV) 
factors in twins (in themselves the focus of Study I). 
 
In the register-based study of twinship and validated asthma outcomes (Study I), we found 
that twins were at increased risk of asthma compared to singletons in early childhood, but not 
from 5 to 18 years of age. This could imply a true difference by age, possibly for different 
asthma phenotypes, or be due to changes in environment occurring between the points in time 
during which the two age cohorts were examined. After adjusting for perinatal covariates 
including gestational age, birth weight, and mode of delivery, twins were at lower risk of 
asthma than singletons – a fact which could be partially attributed to the underlying reasons 
behind early delivery in twins vs. singletons, although this merits further investigation. For 
the purposes of further studies of asthma in twins, however, we found the fact that the 
initially increased risk could be explained by the suggested mediators reassuring. 
 
Secondly, we modelled growth during early childhood using a novel parametric method, 
describing specific features of changes in children’s height and weight from birth to three 
years of age. (Study II) The study featured a unique combination of twin and Swedish child 
health record data, allowing for detailed analyses including the potential to investigate the 
influences of genetic and environmental confounding. At this point in childhood (or perhaps 
because of the broadly defined outcome that we applied) we could not find specific 
differences in early growth in twins with and without asthma beyond a slight delay in the 
timing of maximum growth velocity during this period. While genetic and environmental 
confounding did not appear to have influenced the delay in growth, the association 
disappeared following adjustment for factors associated with foetal growth, indicating that 
perhaps foetal growth was the true origin of the later growth pattern. 
 
In contrast, the influence of the transmitted factors was more convincing – both for asthma 
(whether it was defined based on parental report or validated register-based outcomes) and 
related allergic diseases. (Study III) Although the additive genetic effects were large and 
highly significant in the twin models, the associations between the selected genetic variants 
and this phenotype only explained a fraction of the total variation. While this was not 
surprising given that we had chosen a small number of variants, the fact that these high-risk 
variants proved to be highly specific for childhood asthma was interesting – not only in the 
light of high heritability of all our investigated phenotypes, but because of the previously 
established comorbidity within this group. 
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Finally, more than three hundred CpG loci were significantly associated with asthma within 
the STOPPA cohort. (Study IV) But despite this relatively large number, there was limited 
agreement between our results and previously published data – as well as very few prior 
replications within the field. A possible reason for this finding may be that there have been 
very few studies with the potential to correct for confounding by cell type or genetics. In the 
discordant twin cohort design of STOPPA, we could do both – and found that adjusting for 
either of these factors significantly changed our results. When the prior associations 
weakened beyond the point of statistical significance, we concluded that DNA methylation in 
asthma is highly correlated to factors varying with the disease. To get to true disease-specific 
epigenetic features, the next generation of epigenetic studies must move beyond confounding 
by cell type, genetics, and other possible biological sources of confounding.  
 
In summary, this thesis combined a unique set of data sources with novel methodologies to 
investigate a few well chosen angles of the two quintessential causes of every phenotype: 
genes and environment. For childhood asthma and the transmitted and acquired factors 
investigated here, the balance still seems to favour genetics. But these angles are a few of 
many, and the cross-sectional field of paediatric (epi)genetic epidemiology will have much to 
say about childhood asthma and allergies for many years to come. 
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Don't adventures ever have an end? I suppose not. Someone else always has to carry on the 
story. — J.R.R. Tolkien, The Lord of the Rings 
10. IMPLICATIONS FOR FUTURE RESEARCH 
 
We’ve concluded that there is still much to be done – but where to start? Based on the 
findings within this thesis, the following are a few questions and possible continuations 
which could bring the field further. 
 
Twins were not at higher risk for asthma after adjusting for important mediators, but it is still 
intriguing to consider the potential that they may be healthier compared to singletons born at 
the same gestational age. Looking purely at the prevalence or incidence of asthma in twins vs. 
singletons (as in Study I) might only be scratching the surface. It is possible that the features 
of asthma are different between twins and singletons, and comparative studies of twin and 
singleton cohorts selected from similar populations and studied with similar methodology 
could be used to gain further knowledge on this matter. 
 
Study II concerned the influence of genetic confounding on the possible association between 
early growth parameters and asthma. But what about the genetic influences on the early 
growth in itself? While it’s known that outcomes of early growth are highly heritable, to my 
knowledge there has been no previous investigation of the heritability of features of growth 
on parameter-based level before. The data collected within CATSS-15 and CATSS-
15/DOGSS would be an excellent setting. 
 
In Study III we presented new heritability estimates for some allergic phenotypes related to 
asthma – some of which had few previous estimates. But all of the estimates we presented 
came from univariate twin models. Some bivariate models (i.e. of the shared heritability) of 
allergic phenotypes have been presented previously – but it could be interesting to look at the 
intersection between the group of related phenotypes, for example asthma, hay fever, and 
eczema, and also to add food allergy – a phenotype that has rarely been included in these 
studies previously. It might be particularly interesting to do this comparison in parallel with 
LD regression based on GWAS data from the same cohort. 
 
Study IV only scratched the surface of biological confounding sources in studies of DNA 
methylation for paediatric outcomes. Further exploration of the association and potential 
genetic confounding of DNA methylation patterns in factors closely related to childhood 
asthma could show the width of what epigenetic changes really represent. 
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brightly, like a beacon of inspiration for what a PhD education at MEB could be. I hope I 
managed to do your hopes for the future of MEB and the PhD student group justice! Anne 
Örtqvist – always one step ahead – thank you for being a constant source of motivation! It 
wouldn't have been the same without you, either. Lisa Möller – for encouraging me to 
diversify my education and my career. Sandra Eloranta – you trigger my impulses to pursue 
cool and slightly crazy challenges. The world needs more like you. Therese Ljung – you 
were a great companion and sounding board at the top of the PhD group – I really enjoyed 
working with you. Tong Gong – your bright laughter and helpful spirit were pleasant 
additions to my days. Tracy Peters – for bringing your upbeat American vibes to improve 
the mood – whether over tea, dinner, or drinks. Thank you also to Alexander Viktorin, 
Amir Sariaslan, Andrea Ganna, Anna Johansson, Emma Frans, Iffat Rahman, Karin 
Sundström, Katherine Kasiman, Lovisa Brehmer née Högberg, Maria Schelin née 
Sandberg, Martin Cederlöf, Martin Fransson, Miriam Elfström, Myeongjee Lee, Qi 
Chen, Ralf Kuja-Halkola, Robert Karlsson, Sara Raposo née Christensen, Stephanie 
Bonn, Therese Andersson, Thomas Frisell, and Viktoria Johansson, who went ahead.  
 
The current PhD students at MEB, including Agnes Ohlsson Gotby, Andreas Jangmo, 
Andreas Karlsson, Caroline Weibull, Carolyn Cesta, Daniela Mariosa, Elisa Longinetti, 
Elisabeth Dahlqwist, Emilio Ugalde, Favelle Lamb, Fei Yang, Frida Lundberg, 
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Hannah Bower, Ida Karlsson, Isabell Brikell, Isabella Ekheden, Johanna Holm, 
Johanna Sieurin, Kathleen Bokenberger, Laura Ghirardi, Linda Abrahamsson, Malin 
Ericsson, Nelson Ndegwa, and Shuyang Yao. You may feel like the day is far away, but 
you’ll be next. I won’t pretend the final countdown isn’t the most hectic part of the road – but 
it’s probably the most enjoyable one, too. Don’t forget to have fun! 
 
Among the current MEB PhD students, a special mention to Johanna Holm – for the best 
fika-walks, conversations about life, academia, and everything – and for refreshing my 
thoughts at some of the points when I've needed it the most. You've made me better – as a 
researcher, leader, and person. Thank you. 
 
My friends from around the globe: Amanda Roberts, Anett Wargmo, Ashley Dawn Lu, 
Chelsea Heidt, Clarissa Alberts, Hannah Stevens, Jacqueline Cooke, Jenny Hiltunen, 
Josephine Hellberg, Julia Svechnikova, Sophie Buchanan, Tammar Gino, and Ziang 
Her. Distance means nothing when one has friends like you.  
 
I am incredibly lucky to come from a large and wonderful extended family. You have 
always been there to celebrate all of my achievements – I hope you will particularly enjoy 
sharing this one! Somehow, my godmother Kerstin Nordlund-Malmegård seemed to know 
I would combine medical school and research long before I did. She and her twin sister Ulla 
Nordlund-Gustafsson have always encouraged me to pursue my goals.  
 
My aunt and godmother Viveca Ullemar Friberg does not just collect gems – she is one. 
 
My maternal grandmother Rut, thank you for pointing out that I work too much (you’re 
probably right) and for instilling a rather fervent hope in the power of genetics because I can 
think of no better way of growing old than the way you have. Even I can hardly believe 
you’re really 99! 
 
My brother Leo: growing up alongside you has made me who I am. I am proud to be able to 
call myself your sister, and I admire you more than you know. You’re the best.  
 
My father Bengt, who showed me the sky is not the limit, but something very much within 
reach. Thank you for indulging my incessant ambition – your support has been the wind 
beneath my wings. And my mother Carina, who put science in my DNA. While my thesis is 
not going to result in a second Ullemar’s formula (probably just as well – after all, what 
would they name it?) it is going to bring another Dr. Ullemar into the world. And yet, none of 
what I’ve accomplished would have been possible if it had not been for the first one.  
Mamma, this is just as much your work as it is mine. 
  
To all current and future bearers of the Ullemar name: you can do anything you set your mind 
to. Reach for the stars – I’ll be cheering you on. 
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